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ABSTRACT OF THE DISSERTATION
Biochemical and Functional Characterization of the LEDGF/p75-MeCP2 Interaction in
Tumor Cells
by
Lai Sum Leoh
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, September 2011
Dr. Carlos A. Casiano, Chairperson
The lens epithelial derived growth factor p75 (LEDGF/p75) is a novel prosurvival and stress-inducible transcription co-activator that protects mammalian cells
from various environmental stresses such as oxidative stress, heat shock, and serum
starvation. This emerging cancer-related protein is highly expressed in prostate tumors
and other tumor types and promotes resistance to chemotherapy in cancer cells.
LEDGF/p75 is also involved in acquired immunodeficiency syndrome (AIDS) since it
interacts with HIV-1 integrase to facilitate the integration and replication of the HIV
virus in human cells. In addition, LEDGF/p75 has been shown to interact with MLL
(mixed lineage leukemia)/menin transcription complex in leukemia cells to facilitate the
transcription of cancer-associated genes and leukemic transformation. In order to
understand the mechanisms by which LEDGF/p75 contributes to cancer development, we
explored its interactions with other transcription factors and the influence of these
interactions on its transcriptional activity. Using complementary molecular, biochemical,
and cellular approaches we discovered that the amino-terminal region of LEDGF/p75
interacts with the transcription regulator and methylation associated protein MeCP2 in
prostate cancer cells and other cancer cell types. We observed that both proteins regulate

xvii

the expression of the heat shock protein 27 gene by transactivating its promoter region.
We propose that the interaction between LEDGF/p75 and MeCP2 modulates the
expression of cancer-associated genes in response to environmental stressors. These
findings provide a plausible mechanism that can be targeted for the treatment of
advanced prostate cancer, which is the second leading cause of cancer deaths in the
United States, with a disproportional burden among African American men.

xviii

CHAPTER ONE
INTRODUCTION

The Prostate
The prostate is a gland that surrounds the urethra at the base of the bladder and
produces secretory proteins to the seminal fluid. It is not required for viability or basal
levels of fertility; thus, its primary significance is its relevance for human disease, as
treatment strategies can disrupt normal urinary, bowel and sexual functions [1]. The
prostate contains three defined regions (Figure 1) [2-5]: the peripheral zone, the
periurethral transition zone, the central zone, together with an anterior fibromuscular
stroma [6]. Benign prostatic hyperplasia (BPH) arises from the transition zone, while
prostate carcinomas are mostly found in the peripheral zone [1].

Prostate Cancer
Prostate cancer is generally multifocal, since primary tumors often contain
multiple independent histologic foci of cancer that are often genetically distinct [7-10]. In
contrast, despite the phenotypic heterogeneity of metastatic prostate cancer [11],
molecular and cytogenetic analyses show that multiple metastases in the same patient are
monoclonal [12-13]. These findings suggest that metastatic prostate cancer may arise
from the selective advantage of individual clones during cancer progression.
Alternatively, this could be a result of therapeutic interventions such as androgen
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Figure 1. Schematic illustration of the anatomy of the human prostate by Abate-Shen et
al. [1]. In the illustration the three main regions of the prostate can be observed the
peripheral, transition and central zone.

2

deprivation and chemotherapy, which may differentially target cells of varying malignant
potential. Although human prostate cancer displays significant phenotypic heterogeneity,
the majority of prostate cancers are adenocarcinomas.

Statistics
Prostate cancer (PCa) is the most common male cancer and the second leading
cause of male cancer associated deaths in the United States. It is estimated that over
217,730 men will be diagnosed with and 32,050 men will die from PCa in 2010 [14].
Based on rates from 2003-2005, one in six men will be diagnosed with PCa during their
lifetime [15] and a 3.4% chance to die because of this disease [16-17]. The number of
men with PCa increases dramatically as the population of males over the age of 50 grows
worldwide. Therefore, understanding the causes that increase the risk of PCa has become
an important epidemiological concern. Epidemiological studies have lead to the
identification of various risk factors that can increase susceptibility to PCa.

PCa Risk Factors
Risk factors that promote prostate carcinogenesis include family history, race,
oxidative stress and aging, and diet. These factors will be discussed below.

Family History
Hereditary factors account for a small percent (~10%) of PCa [1]. The first putative
hereditary prostate cancer locus, HPC1, was localized to chromosome 1q24–q25 [18].
Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International
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Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses
confirmed significant linkage evidence at chromosome 22q12 and at twelve other regions
[19]. The major contributing prostate cancer susceptibility locus found in southern and
western Europe is PCAP, predisposing for PCa, which maps to 1q42–q43 [20-21], while
CAPB, 1p36, is reported in families with a history of both prostate and brain cancers
[22]. Other prostate cancer susceptibility loci includes HPC2 at 17p11, Xq27-28 (HPCX)
[23-25], hereditary prostate cancer locus 3HPC20 20q13 [26], Ribonuclease L
(RNASEL), macrophage-scavenger receptor 1 (MSR1), CHEK2, vitamin D receptor and
paraoxonase 1 (PON1) [18, 27-31]. In addition, mutations in BRCA gene was also found
to be strongly associated with rapidly progressing lethal prostate cancer [32]. VEGF and
HSP70-hom polymorphisms were also reported to be significantly associated with PCa
susceptibility and prognosis [33].
A series of sequence variants located along chromosome 8q24 have been
associated with an increased risk of PCa [34-36], as reported by more recent genomewide association studies (GWAS) [37-39]. Colon, breast and ovarian [40] risks are also
associated with mutations of 8q24. In the first stage of the UK GWAS, 20 tagSNPs out of
53 significant tagSNPs were on chromosome 8q, and 6 were on chromosome 17q (8,12),
consistent with previous GWAS [37, 41]. In addition, seven new susceptibility regions on
human chromosomes 3, 6, 7, 10, 11, 19 and X were linked to a risk of developing PCa
[42]. Under multiplicative risk model, and in combination with previously reported SNPs
on 8q and 17q, these loci explain 16% of the familial risk of the disease [43]. Recently,
seven new prostate cancer susceptibility loci were identified on chromosomes 2, 4, 8, 11
and 22 through a genome-wide association study in which 43,671 SNPs in 3,650 PCa
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cases and 3,940 controls were genotyped [44]. Carriers of five high-risk alleles in the
androgen receptor (AR), Cytochrome P450 (CYP17), and Steroid-5-alpha-Reductase type
2 (SRD5A2) genes were reported to have a two-fold excess risk to develop PCa [45].
Disappointingly, however, other population-based studies did not identify many of the
loci identified in GWAS, including analyses of groups with high-risk for prostate cancer,
such as African-Americans [46].

Race
Disparities in the incidence and mortality of PCa patients with different racial
backgrounds have lead to the observation that African American (AA) men have one of
the highest reported incidence rates in the world, with distinctly higher mortality
compared to White American (WA) men [47]. AA men develop the disease 1.6 times
more frequently with a mortality rate 2.5 times greater than their WA men counterparts of
the same age [48-50]. In addition, SEER (Surveillance Epidemiology and End Results)
incidence statistics reported that PCA incidences per 100,000 men were 146.3 in WA and
231.9 in AA men, compared to 82.3 in Asian/ Pacific Islander (A/PI) (these rates are
based on cases diagnosed in 2002-2006 from 17 SEER geographic areas) [51]. Death
rates per 100,000 men were 23.6 in WA, 56.3 in AA, and 10.6 in A/PI. AA men are
younger at the time of diagnosis, have tumors that are higher in stage and grade, and have
a shorter survival rate when compared to WA men [52]. Fowler et al. compared the
outcomes of 396 WA men and 524 AA men with PCa diagnosed between 1982 and 1992
and reported that localized PCa was more lethal in AA men than in WA men [53].
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An analysis of 48 articles that provided data that enabled an estimated hazard
ratio and standard error to be derived allowed comparison of AA and WA men in terms
of overall survival, PCa survival or biochemical recurrence. One out of every 125 AA
men with PCa will die of the disease within 10 years due to biological factors of their
ethnicity, having adjusted for age, clinical presentation and socioeconomic status [54].
Similarly, a pooled all-cause mortality hazard ratio comparing AA to WA men following
a diagnosis of PCa was calculated based on summary statistics from 17 studies. Of the 14
cancers compared, blacks were at a significantly higher risk of cancer-specific death only
for cancer of the breast, uterus, or bladder [55]. Interestingly, Cooney et al. reported that
African-American families contributed disproportionately to the observation of linkage to
hereditary prostate cancer gene HPC1 [56].
Others propose that the reasons for racial differences in PCa incidence and
mortality are multifactorial, including socioeconomic status, access to health care, genetic
susceptibility and diet [57]. However, three recent studies with large cohorts indicated
that after correction for socioeconomic status, disparities in PCa incidence still persist
among AA, suggesting that biological factors might be involved [58-61].
Wallace et al. [62] compared the expression profile of primary prostate tumors
from 33 AA men and 36 WA men by using microarray analyses and identified two genes
that were upregulated in AA men when compared to WA men: PSPHL and CRYBB2
[62], which were reported in eye diseases but had unknown function in the prostate.
Further studies will be needed to confirm their importance in PCa disparities. It has also
been reported that AA men have higher levels of androgen metabolites as compared to
WA men, such as higher circulating levels of testosterone [63-64]. In addition, prostate-
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specific antigen (PSA) values at diagnosis are greater, and high grade prostatic
intraepithelial neoplasia (HGPIN) expression is more common in AA men compared to
WA men [53], [65-66]. Insulin-like growth factor one (IGF-1) and IGF binding protein 3
(IGFBP-3) levels are higher in WA compared to AA men [67].
The role of somatic genetic mutations, including loss or amplification or specific
genes in prostate tumors, has been correlated with the natural history of PCa progression
and therefore clinical prognosis [68-69]. Inherited mutations in genes involved in
regulation of somatic DNA damage or repair and metabolism of steroid hormones that
induce the growth of PCa may be associated with disease prognosis if they are involved
in metabolic events that lead to tumor progression [70].

Oxidative Stress, Inflammation and Aging
Oxidative stress results from the imbalance of reactive oxygen species (ROS) and
detoxifying enzymes that control cellular levels of ROS, which leads to cumulative
damage to lipids, proteins, and DNA. Evidence linking oxidative stress and PCa initiation
include correlative studies showing that major antioxidant enzymes are reduced in human
PIN and PCa, together with a coincidental increase in the oxidized DNA adduct 8-oxy7,8,dihydro-2′-deoxyguanosine (8-oxy-dG) [71]. APE/Ref1, a multifunctional enzyme
involved in redox control of key enzymes and base excision repair, is up-regulated in
PCa, while polymorphisms in the APE gene are associated with increased PCa risk [7273]. Nkx3.1 loss of function leads to deregulated expression of oxidative damage
response genes and increased levels of 8-oxy-dG, correlating with the onset of PIN [74],
while its gain of function protects against DNA damage in PCa cell lines [75].
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The prevalence of PCa increases by age group, with 3% for men aged 60-64, 10%
for men aged 70-74, 15% for men aged 80-84, and 14% for men over 85 years old [16,
76]. Autopsy studies revealed PCa incidence up to 60% in men aged 80 and above [7778]. These numbers are expected to increase with an estimated 20% of the population at
65 years or older in year 2030, compared to 13% today [79]. Increasing evidence has
indicated that oxidative stress is associated with aging and cancer through an imbalance
in cellular prooxidant-antioxidant status [80-82].
Young healthy individuals are equipped with adequate antioxidant defense
mechanism to protect against free radicals through ROS detoxification enzymes such as
superoxide dismutases (SODs), glutathione peroxidase (GPx), glutathione-S-transferases
(GST), other constitutive and inducible antioxidants, DNA repair enzymes, and other
cellular mechanisms of genomic surveillance, such as cell cycle checkpoint control
systems [83]. In aging individuals, a decrease in detoxification enzyme activities has been
observed [82], leading to progressive accumulation of DNA adducts, increase in DNA
strand-break frequency and point mutations, telomere attrition, and alterations in
methylation pattern [84-86] [82, 87-88]. Stimulation of DNA damage can either arrest or
induce transcription, signal transduction pathways, replication errors, genomic instability,
abnormal function of proteins involved in cellular growth, responses to cellular stress,
and inflammation [89-90], all of which are associated with carcinogenesis [91-93].
In addition, telomere erosion-induced replicative senescence and oxidative stress,
oncogene activation or DNA damage-induced premature-senescence are also linked to
aging [94-95]. The development of an abundant, highly disorganized and fragmented
collagen matrix in the prostate is a result of aging, and promotes oxidative stress [96].
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This leads to the increased expression of stress response proteins such as Apoliprotein D,
as well as the increase in inflammatory infiltrates. Together with redox-induced
biochemical alterations, modulation of redox sensitive transcriptional activators leads to
changes in biological functions of proteins, leading to tumor initiation and malignant
transformation [97-98].
Increased ROS levels in cancer cells correlate with tumor aggressiveness and poor
prognosis [99-100]. One of the major sources of ROS in cancer cells is activated
oncogene-induced upregulation of ROS-producing enzymes as in the case of K-ras
transcriptionally activating endothelial NADPH oxidase NOX1 [101]. Other protooncogenes that induce ROS include SRC [102], c-MYC [103], and overexpression of
receptor tyrosine kinases [104]. Loss of functional p53 also contributes to redox
imbalance and elevated ROS levels. Furthermore, mitochondrial DNA (mtDNA)
mutations associated with increased ROS levels due to increased leakage of electrons
have been reported in both solid tumors and leukemia [105-107]. Extrinsic factors such as
inflammatory cytokines (eg: TNFα), nutrient imbalance and hypoxia also result in
dysregulation of ROS production [108-109].
ROS facilitates cancer cells proliferation through the activation of downstream
targets such as the Keap1/Nrf2 pathway, which upregulates various cytoprotective genes
and facilitates cancer progression [110]. The AKT/mTOR pathway ultimately activates
nuclear factor κB (NF-κB) to induce pro-survival signals, and ROS are required for NFκB activation in HeLa cells in response to inflammatory cytokines [111]. The alternative
NF-κB pathway component RelB protects PCa cells from the detrimental effects of
ionizing radiation, in part, by stimulating expression of the mitochondria-localized
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antioxidant enzyme manganese superoxide dismutase (MnSOD) [112]. Cancer cells may
acquire adaptive mechanisms, including the activation of ROS-scavenging systems such
as glutathione (GSH), as well as the inhibition of apoptosis [113], which may lead to
malignant transformation, metastasis and chemo-resistance. Recently, docosahexaenoic
acid (DHA, Omega-3) have been shown to selectively induce human PCa cell sensitivity
to oxidative stress through modulation of NF-κB [114].

Diet
A variety of dietary factors have been implicated in the development of PCa. One
of these factors is higher consumption of polyunsaturated fat. Four case control studies
found a positive correlation between higher intake of polyunsaturated fat and higher risk
of PCa [115-118]. It is speculated that a higher fat intake leads to alterations in the
hormonal profile, increases in oxidative stress, and generation of fat metabolites that act
as protein or DNA-reactive intermediates, thereby increasing the risk for PCa [119-121].
A review reported a statistically significant protective effect in diets high in fruit and
vegetable consumption in 128 out of 156 studies [122-123], suggesting that a high intake
of fruits and vegetables might be a valid tool for cancer prevention.
Other dietary factors implicated with PCa risk are vitamins A, C, D and, E,
selenium and lycopene. Studies suggest that there is a correlation between lower levels of
these vitamins and higher risk of PCa [117, 124-128]. This was confirmed in randomized
double-blind trials showing that a diet supplemented with selenium reduced the risk of
PCa [129-130]. Indole-3-carbinol (I3C), a phytochemical from cruciferous vegetables,
and its major active metabolite 3,3'-diindolylmethane (DIM), stimulate BRCA1 in breast
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and PCa cells and has been shown to protect cells against oxidative stress mediated by
hydrogen peroxide (H2O2) and γ-radiation [131-132].
However, different results were obtained from the Prostate Cancer Prevention
Trial, which examined nutritional risk factors for PCa among 9,559 participants. Highgrade cancer was associated with high intake of polyunsaturated fats, but protective
effects of dietary and nutrition supplements were not shown (United States and Canada,
1994-2003) [133].
Traditionally, diets comsumed by African Americans are higher in fat intake and
lower in fruit and vegetable consumption in comparison to other ethnic groups [134] such
as the Japanese, who consume a relatively low fat diet with high intake of soy products,
and have lower PCa risk [135]. However, it has been observed that as the fat content of
Japanese diet increases towards Western levels, their incidence of PCa has also increased
[136], [137-138]. Physical inactivity and higher fat and meat intake in Western countries
has been proposed to contribute to the increase in cancer risk [139]. Obesity results in an
increase in serum concentrations of estrogen, testosterone, insulin, insulin-like growth
factor 1 (IGF-I), which have all been linked to PCa, and leptin, which has been associated
with high-grade PCa [140-143]. An increased level of inflammation is also observed, as
seen in increased levels of interleukin 6 (IL-6) and tumor necrosis factor-α [144]. Chronic
inflammation has been reported to be associated with proliferative inflammatory lesions
that may lead to prostate tumors [145-147].
Although some studies linked obesity to modestly reduced incidence of low-grade
disease [148]; others found no association between obesity and PCa. However, obese
men have been linked to slightly decreased PSA levels [149-153] and enlarged prostates
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[154-155], which leads to delayed detection of PCa and worse clinical outcome. Obese
AA men with low PSA levels have been observed to have more aggressive prostate
tumors than non-AA men [156]. In many trials, obesity increases the risk of more
aggressive PCa, by a modulating effect of adiponectin, insulin or IGF-I, and may
decrease either the occurrence or the likelihood of diagnosis of less-aggressive tumors
[122, 157].

Prostate Cancer Detection
Common tests used to screen for PCa include digital rectal exam (DRE) and PSA.
Despite the poor accuracy of DRE (59%) [158], it is used routinely for PCa screening
because of its ability to detect cancer in some men with normal PSA levels with small
and well differentiated tumors [159]. However, early cancers are rarely palpable, and
clinically important cancers are usually located in distant regions of glands evasive to
digital palpation [160].
Although the levels of PSA are higher in men with PCa, they are also elevated in
other conditions such as benign prostatic hyperplasia (BPH), prostatitis, or even induced
by medications or medical procedures, leading to many unnecessary biopsies on patients
[161]. The inadequacies found in PSA testing underscore the need for new PCa
biomarkers. Most recent biomarkers include Prostate cancer gene 3 (PCA3) and CD14.
The Progensa™ (Gen-Probe Inc., San Diego, CA, USA) PCA3 urine test, is a
quantitative test that detects PCA3 mRNA levels, which are overexpressed in more than
95% of primary prostate tumors [162]. Urinary CD14 is highly specific (>81%) and
allows the distinction of BPH from cancer with high specificity (84-100%) when
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combined with urinary prostate-specific antigen [163]. Future diagnostic tools with
combinations of multiple biomarkers will optimize the detection and characterization of
PCa.

Progression of Prostate Cancer
The progression from a normal prostate to PCa is illustrated in Figure 2. PCa
progression starts with a prostatic lesion called proliferative inflammation atrophy (PIA),
proceeding towards prostatic intraepithelial neoplasia (PIN), leading to PCa and ending
in metastasis [164].

PIA
PIA usually occurs in the periphery of the prostate, consisting of focal areas of
epithelial atrophy that fail to differentiate into columnar secretory cells [164-167]. PIA
has been associated with chronic inflammation, arising as a consequence of the
regenerative proliferation of prostate epithelial cells in response to injury caused by
inflammatory oxidants [164]. Some characteristics in the development of PIA from a
normal prostate are the infiltration of lymphocytes, macrophages, and neutrophils, which
might be caused by repeated infections, dietary factors, and/or the onset of autoimmunity
[145]. These phagocytes release reactive oxygen and nitrogen species causing DNA
damage, cell injury, and cell death, thus triggering the onset of epithelial cell regeneration
[145]. Regions of PIA are also often located in proximity with PIN and adenocarcinoma,
and have been proposed to represent a precursor lesion for PCa [164, 168].
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Figure 2. Schematic drawing of PCa progression by Nelson et al. [166]. The normal
prostate has differentiated basal and columnar cells. As it progresses to proliferative
inflammatory atrophy (PIA) focal areas of epithelial atrophy develop and, cells fail to
differentiate into columnar secretory cells. In prostatic intraepithelial neoplasia (PIN)
lesions disruption of the basal cell layer can be seen as well as nuclear abnormalities.
When it progresses to PCa the basal cell layer is lost as well as the distinct glandular
architecture. Cells appear dedifferentiated.
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PIN
PIN is widely accepted as a precursor for prostate cancer, supported by the
finding of PIN lesions in the peripheral zone, where PCa develops [169], although this
relationship has not been demonstrated conclusively [168]. PIN is histologically
characterized by the appearance of luminal epithelial hyperplasia, loss of basal cells,
enlargement of nuclei and nucleoli, cytoplasmic hyperchromasia, and nuclear atypia
[170] (Figure 2). PIN lesions precede those of the carcinoma by ten years [171], and
possess chromosomal abnormalities that resemble those found in early stages of PCa
[172-175]. The architectural and cytological features of PIN also resemble those found in
PCa [176]. In addition, markers of differentiation found in early PCa are found in PIN
lesions [172, 177]. The main differences between them are that PIN lesions have intact
basement membrane and do not produce high levels of PSA compared to the initial stages
of PCa [172, 176].

Prostate Carcinogenesis
Normal prostate epithelial cells have a relatively low rate of proliferation. PIN
and localized PCa show a seven to ten fold increase in the rate of proliferation [178].
Also, localized PCa is characterized by a continued proliferation of genetically unstable
luminal cells and accumulation of genomic changes [145], which are observed in the loss
of regions of chromosomes 10q and 13q. The loss of chromosome 10q has been found in
approximately 50-80% of PCa, specifically loci 10q23.1 and 10q24-q25 [174, 179-186].
Loss of Phosphatase and tensin homolog (PTEN) gene results in activation of protein
kinase B (PKB), leading to decreased sensitivity to cell death [1, 187-188], Evidence
implicating PTEN as a key event in prostate carcinogenesis include observations that
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PTEN is mutated in four PCa cell lines and PTEN heterozygous mutant mice developed
prostatic epithelial hyperplasia and dysplasia [189-192]. Loss of parts of chromosome
13q, including a region for the retinoblastoma (Rb) gene, occurs in 50% of prostate
tumors [193-195]. Loss of Rb protein expression has been observed in localized as well
as in more advance stages of PCa [183, 196-197].
Epigenetic perturbations are also important contributing factors in prostate
carcinogenesis, and may provide useful biomarkers for disease progression [198-200].
DNA methylation mediated gene silencing has been reported in genes involved in signal
transduction, hormonal response, cell cycle control, and oxidative damage response, such
as glutathione-S-Transferase Pi (GSTP)1. Global changes in chromatin modification
correlates with cancer progression [201-202], as seen in trimethylation of lysine residue
27 of histone H3 (H3K27-me3), mediated by the histone methyltransferase enzyme Ezh2,
a key oncogenic driver of advanced disease and metastasis [203]. Increased levels in
prostate cancer are also associated with repression of tumor suppressor genes such as
Disabled homolog 2-interacting protein (DAB2IP), a member of the Ras GTPase family
[204].

Treatment of PCa
Localized PCa is the most commonly diagnosed stage in patients. The main
treatment for this stage is either radiation therapy or prostatectomy [205] combined with
hormonal therapy depending on risk status [27]. Unfortunately, relapse often occurs with
aberrant prostate tumor growth. A rapid rising in the serum PSA levels is usually the first
sign of failure to treatment is [27]. These patients are then subjected to androgen ablation
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therapy through either chemical or surgical castration, which generally kills androgen
reliant prostate cells but may promote vasomotor flushing, loss of libido, erectile
dysfunction, gynaecomastia, weight gain, osteoporosis and loss of muscle mass [205].
However, the majority of such treatments ultimately result in the recurrence of highly
aggressive and metastatic androgen independent PCa known as hormone refractory
prostate cancer (HRPC) or castration-resistant metastatic prostate cancer (CRPC) [1,
206]. The arise of HRPC is made possible by variable combinations of clonal selection,
adaptive upregulation of anti-apoptotic genes, ligand-independent activation of the
androgen receptor, and alternative growth factor pathways [207-215]. Chemotherapy
agents used in the treatment of HRPC fall into three categories: 1) DNA intercalating
agents, 2) alkylating compounds, and 3) microtubule stabilizing agents [205]. Current
treatment of HRPC using the microtubule stabilizing drug docetaxel has shown a three
month increase in the overall survival in patients with HRPC [216-217].
Chemoresistance in PCa has been associated with the overexpression of survival
proteins or downregulation of pro-apoptotic proteins. Survival proteins such as Bcl-2,
Bcl-XL, members of the inhibitor of apoptosis protein (IAP) family, and heat shock
proteins (hsp), as well as the kinase Pim-1 and the tumor suppressor p27, may result in
aggressively growing tumors and contribute to resistance to chemotherapeutic agents
[218]. Since most advanced tumors are insensitive to chemotherapy, the resistance
provided by these survival proteins becomes a major problem at the clinical level. For
this reason, new molecules that influence these survival pathways, administered in
combination with cytotoxic drugs have become the preferred strategy in clinical studies
to overcome intrinsic drug resistance [218]. We will discuss below various survival

17

proteins that are being studied mainly in PCa and that contribute to chemoresistance,
expecially to taxanes.

PCa Survival Proteins
Bcl-2
Bcl-2 is a proto-oncogene localized on the mitochondrial outer membrane that
prevents apoptosis induced by different stimuli [219] by suppressing the release of
cytochrome c from the mitochondria [220]. It is the primary member of the Bcl-2 family
of proteins which regulates the assembly of pro-caspase/apoptosome complex [221]. All
members of the Bcl-2 family contain one of four conserved Bcl-2 homology domains
(BH1-BH4). Members of this family are divided in 3 categories: anti-apoptotic,
multidomain pro-apoptotic, and BH3-only pro-apoptotic members [222]. In PCa, Bcl-2
overexpression is associated with progression to an androgen-independent form [223].
Increased expression of Bcl-2 induces resistance to androgen ablation therapy, while its
inhibition delays progression to androgen-independence and sensitizes PCa cells to
therapy [224-225]. PC3 cells treated with G3139 (antisense oligodeoxynucleotides for
bcl-2) followed by docetaxel (DTX) treatment resulted in a higher apoptotic rate than
treatment with DTX alone [226]. Furthermore, Bcl-2 was overexpressed in the DTXresistant gastric cancer cell line BGC-823 but not in its non-resistant counterpart [227]. In
the androgen-responsive prostate cancer line, LNCaP, overexpression of Bcl-2 permits
continued growth in vitro and tumor formation in vivo despite androgen deprivation
[228].
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Bcl-xL
Bcl-xL is a member of the Bcl-2 family with anti-apoptotic properties. Like Bcl-2,
Bcl-xL regulates the mitochondrial membrane potential and can block the release of
cytochrome c and apoptosis inducing factor (AIF) into the cytoplasm [229-230].
Krajewski et al. observed that 100% of prostate adenocarcinoma cases stained positively
for Bcl-xL, with correlation between stain intensity and increasing Gleason score [231].
A study combining antisense oligos against Bcl-xL and DTX (as well as other cytotoxic
drugs) in the PCa cell lines PC3 and LnCaP [232] showed that inhibition of Bcl-xL
sensitized these cells to DTX-induced death [232]. Recently, Gleave’s group showed that
inhibition of both Bcl-2 and Bcl-xL with bispecific antisense oligos sensitized LnCaP
cells to DTX-induced cell death [233].
In another study, mRNA expression levels of all six antiapoptotic Bcl-2 subfamily
members was investigated in 68 human cancer cell lines. Mcl-1 represents the antiapoptotic Bcl-2 subfamily member with the highest mRNA levels in the lung, prostate,
breast, ovarian, renal, and glioma cancer cell lines. Prominent expression of Bcl-2 seems
to be limited to leukemia cell lines and not in solid tumor cell lines [234]. A subsequent
immunohistochemistry (IHC) investigation of 64 adenocarcinomas of the prostate found
that 25, 100, and 81% of the tumor samples exhibited observable levels of Bcl-2, Bcl-xL,
and Mcl-1, respectively [235]. Furthermore, pre-clinical studies have shown that tumors
highly expressing Mcl-1 are typically resistant to compounds that selectively target Bcl-2
and Bcl-xL [236-237]
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The Inhibitor of Apoptosis Proteins
The inhibitor of apoptosis proteins (IAPs) comprise a family of proteins with one
or more baculovirus IAP repeat (BIR) domain repeats. To date, only eight members have
been identified: c-IAP1, c-IAP2, NAIP, Survivin, XIAP, Bruce, ILP-2, and Livin [221].
IAPs can block caspase 9 and caspase 3/7 activity leading to cell survival, and can be
negatively regulated by Smac, Omi, and XAF-1 [238]. Krajewska et al. were the first to
show overexpression of several IAP members (cIAP1, cIAP2, XIAP, and survivin) in
PCa tissues [239]. In addition, increased levels of these IAPs were observed during
disease progression in a transgenic mouse model of PCa [239]. Survivin is associated
with cell proliferation and has a role in 1a,25-dihydroxyvitamin d(3) induced cell growth
inhibition in PCa [240]. A recent study show survivin was not detected in cytoplasm of
epithelial cells but exhibited increasing expression correlating to Gleason score [241].

Survivin
Survivin has been shown to mediate resistance to paclitaxel therapy in PCa cells.
Adenoviral inhibition of survivin lead to sensitization to cell death induced by paclitaxel
in PC3, DU145 and LnCaP cells [242]. Small inhibitory RNA (siRNA) -mediated downregulation of survivin in PC3 cells showed lower tumor formation in nude mice
xenografts in vivo [243]. In addition, survivin antisense oligonucleotide (ASO) potently
downregulated survivin expression in human cancer cells derived from lung, colon,
pancreas, liver, breast, prostate, ovary, cervix, skin, and brain. Inhibition of survivin
expression induced caspase-3-dependent apoptosis, cell cycle arrest in the G2-M phase,
and multinucleated cells and sensitized tumor cells to chemotherapeutic-induced
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apoptosis. Antisense survivin (LY2181308) is being evaluated in a Phase II clinical trial
in combination with DTX for the treatment of PCa [244]. Intratumoral injection of p53
and anti-survivin inhibited the growth and survival of tumor xenografts in a nude mouse
model [245]. Stimulation with IGF-1 led to increased survivin expression in PCa cells,
which is abolished by the mTOR (mammalian target of rapamycin) inhibitor, rapamycin.
Rapamycin, alone or in combination with suboptimal concentrations of taxol, was shown
to reduce survivin protein levels, and decrease viability of PCa cells [246].
PTEN silences the expression of survivin independent of p53, via direct
occupancy of the survivin promoter by FOXO1 and FOXO3a transcription factors.
Expression of survivin and PTEN was found to be inversely correlated in cancer patients.
[247-249]. Other pivotal tumor suppressors, including p53 [250-251], Adenomatous
polyposis coli (APC) [252], or sirtuin (silent mating type information regulation 2
homolog) 1 (SIRT1) [253] have been shown to acutely silence the survivin gene via
different mechanisms.

Clusterin
Clusterin (CLU) is a cytoprotective chaperone protein expressed in virtually all
tissues and found in all human fluids [254-256]. CLU is upregulated under conditions of
cellular stress [257], such as oxidative stress [258], ionizing radation, and heat shock
[259]. Its role has been documented in PCa for paclitaxel/docetaxel resistance as well as
in renal, breast, and lung tumor cells. Moreover, it is abnormally upregulated in
numerous advanced stage and metastatic cancers spanning prostate, renal, bladder, breast,
head and neck, colon, cervical, pancreatic, lung carcinomas, melanoma, and lymphoma.
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In the prostate, its expression levels have been correlated with pathological grade on
biopsy [256, 260]. CLU expression is downregulated in tumor samples in comparison
with benign matched tissues [261], as well as in both low- and high-grade PCa,
suggesting early event in PCA onset [262-263]. Meta-analysis of available microarray
data shows that CLU mRNA is significantly downregulated in PCa tissue compared to
normal prostate in 14 out of 15 independent studies[264]. However, its mRNA expression
increased in LNCaP tumors after radiation and decreased radiosensitivity of tumors
[265]. Contradictory reports regarding location of CLU expression: epithelial versus
stromal compartment [266-267], suggests the different subcellular location of different
forms of CLU, which may play different roles in PCa.
It is noteworthy that only the cytoplasmic/secretory clusterin form (sCLU), and
not the nuclear form, is expressed in aggressive late stage tumors, which is in line with its
antiapoptotic function. Most significantly, sCLU expression is documented to lead to
broad-based resistance to other unrelated chemotherapeutic agents such as doxorubicin,
cisplatin, etoposide, and camphothecin. Resistance to targeted death-inducing molecules,
tumor necrosis factor, Fas and tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL), or histone deacetylase inhibitors can also be mediated by sCLU. The actual
mechanisms for sCLU induction are unclear but signal transducer and activator of
transcription 1 (STAT1) is required for its constitutive upregulation in docetaxel-resistant
tumor cells. In addition, sCLU appears to stabilize Ku70/Bax complexes, sequestering
Bax from its ability to induce mitochondrial release of cytochrome c that triggers cell
apoptosis [268].
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Recently, it was shown that CLU is silenced by promoter methylation in the
murine TRAMP-C2 cell line, as well as in the human prostate cancer cell line LNCaP
[269]. Treatment of PC3 cells with antisense (AS) CLU oligodeoxynucleotide (ODN)
decreased CLU mRNA by >80%. Combined treatment with adenoviral-mediated p53
gene transfer or mitoxantrone completely eradicated PC3 tumors and lymph node
metastases from orthotopic PC3 tumors in 60% and 100% of mice respectively [270].
Combination of CLU AS oligonucleotide with DTX, paclitaxel or mitoxantrone enhanced
antitumor activity of the drugs in vitro and in vivo [271],[256]. Phase I study reported that
an AS CLU, OGX-011, inhibited CLU expression in prostate cancer tissues by more than
90% [272]. A subsequent Phase II study in Patients with Metastatic Castration-Resistant
Prostate Cancer reported that median progression-free survival of patients on OGX-011
and DTX combination treatment was 23.8 months at a median follow up of 35 months,
longer than 16.9 months for patients on DTX in combination with dexamethasone and
prednisone [273]. Strong preclinical and clinical proof-of-principle data provide rationale
for further study of sCLU inhibitors in randomized phase III trials, which are planned to
begin in 2010 [274].
PKB plays a critical role in upregulating cytoplasmic/secretory sCLU, which is
responsible for DTX resistance. Loss of AKT function resulted in loss of sCLU and was
accompanied by chemosensitization to docetaxel and increased cell death via a caspase3-dependent pathway. AKT mediates sCLU induction via signal transducer and activator
of transcription activation, which drive sCLU gene expression [275].
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Heat Shock Proteins
Heat shock proteins (HSPs) are molecular chaperones made up of a set of highly
conserved proteins whose expression is induced by a wide variety of physiological and
environmental insults including chemical and physical stresses [276-277]. HSPs help
cells in adapting to changes in their environment, modifying the structure and interactions
of other proteins, thus allowing them to survive to lethal conditions [278]. Mammalian
HSPs are classified according to their molecular weight: HSP90, HSP70, HSP60 and
small HSPs (15–30 kDa) that include HSP27 [257]. HSPs family members are expressed
either constitutively or regulated inductively, and are present in different subcellular
compartments.
High molecular weight HSPs are ATP-dependent chaperones, and rely on cochaperones to modulate their conformation and ATP binding. In contrast, small HSPs act
in an ATP-independent fashion [279]. Hsp27 and Hsp70 are the most strongly induced
during cellular stress [257], their overexpression increases tumorigenic potential of
rodent cells in syngenic animals [280-284], while HSP70 depletion led to tumor
regression [283, 285].
In stressful conditions, HSPs enhance the ability of cells to cope with increased
concentrations of unfolded or denatured proteins. They achieve this by either stabilizing
or targeting selected proteins for proteasomal degradation [286]. In addition, HSPs
interfere with apoptotic pathways by associating with key effectors of the apoptotic
machinery such as cytochrome c [287], apoptotic protease activating factor 1 (Apaf-1)
[288], or AIF [289], thereby inhibiting both caspase-dependent and caspase-independent
cell death.
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HSP27
HSP27 is abundantly expressed in cancer cells and further increased after various
death stimuli including hyperthermia, oxidative stress, inhibition of tyrosine kinases,
ligation of Fas/Apo-1/CD95 death receptor, radiation or addition of cytotoxic drugs
[288]. Large, non-phosphorylated oligomers of HSP27 are powerful ATP-independent
chaperones preventing aggregation. They decrease ROS in cells, consequently increasing
anti-oxidant defense [290] and neutralizing the toxic effects of oxidized proteins [291],
thus protecting from cell death. Hsp27 large oligomers are also involved in its postmitochondrial anti-apoptotic effect [287]. In contrast, small oligomers stabilize actin
microfilmaents [292] and participate in ubiquitination and degradation of selected
proteins under stress conditions [286]. Hsp27 interferes with caspase activation upstream
of the mitochondria when present in high levels. It prevented cytoskeletal disruption and
Bid intracellular redistribution preceding cytochrome c release in L929 fibroblasts treated
with cytochalasin and staurosporine [293]. Furthermore, phosphorylated Hsp27 directly
interacts with Daxx to prevent cell death [294].
Increased expression of Hsp27 has been observed in hormone refractory prostate
cancer (HRPC). Its inhibition in PC3 cells with antisense (AS) oligos led to the
sensitization to paclitaxel-induced cell death, decreased PC3 tumor progression [295]
growth, and induced apoptosis via caspase-3 activation in vitro [296]. Hsp27 knockdown
in athymic mice bearing LNCaP tumors significantly delayed LNCaP tumor growth after
castration [297]. A second-generation AS oligo, generated using the 2′-O-(2-methoxy)
ethyl (2′-MOE) backbone, targeting Hsp27 inhibited bladder tumor growth in mice,
enhanced sensitivity to paclitaxel, and induced significantly higher levels of apoptosis
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compared with xenografts treated with control oligonucleotides [298]. Recently, it was
reported that Hsp27 interacts with eIF4E and decreases eIF4E ubiquitination and
proteasomal degradation. Overexpression of eIF4E induced resistance to androgenwithdrawal and paclitaxel treatment in LNCaP prostate cells in vitro [299]. In addition,
IGF-1 induces Hsp27 phosphorylation in a time- and dose-dependent manner in PCa.
Hsp27 knockdown destabilizes Bad/14-3-3 complexes and increases the apoptotic rate of
cancer cells [300]. Hsp27 is also involved in metastasis through its association with p38
MAPK, stimulating cancer cell adhesion in the presence of dietary fatty acids [301]. All
these support the importance of targeting HSPs as one method to curb cancer cell growth.
It should be noted that Hsp27 is a target gene of lens epithelium derived growth
factor/p75 (LEDGF/p75) [302], and we cannot rule out the possibility that upregulation
of Hsp27 and other stress proteins by LEDGF/p75 may contribute to DTX resistance
through the ability of these proteins to reduce ROS and prevent lysosomal destabilization.
Studies from our group described in this dissertation have provided evidence that the
stress protein LEDGF/p75, in its interaction with MeCP2, might be involved in the
resistance of PCa cells against chemotherapy by upregulating heat shock protein 27.

The Biology of LEDGF/p75
LEDGF/p75, also known as transcription co-activator p75 [303], autoantigen of
70 kD associated with dense fine nuclear speckles (DFS70) [304], and its alternate
spliced variant LEDGF/p52 were first described in 1998 by Ge and colleagues as
enhancers of transcriptional activation found in the nucleus of cells, with LEDGF/p52
being the more potent co-activator [303].
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LEDGF/p75 and Autoimmunity
Initial studies by Ochs and colleagues indicated that autoantibodies to LEDGF/p75 were
present at significantly high frequencies in patients with atopic dermatitis (AD) [304].
Ayaki et al. [305] confirmed this observation by reporting that some patients with AD
who produce autoantibodies to LEDGF/p75 had cataracts, and that these autoantibodies,
when concentrated, exhibited cytotoxic activity against lens epithelial cells in monolayer
or organ cultures. Autoantibodies to LEDGF have been found in patients with
inflammatory conditions associated with eye and skin disorders such as Vogt-KoyanagiHarada syndrome, sympathetic ophthalmia, Behcet’s disease, sarcoidosis, alopecia areata,
interstitial cystitis, and atypical retinal degeneration [306-308], as well as diverse organbased and systemic autoimmune diseases, nonspecific musculoskeletal complaints, and
miscellaneous inflammatory conditions [309]. Taken together, these studies suggest that
autoimmunity to LEDGF/p75 is associated with inflammatory conditions in which this
protein might be upregulated, leading to loss of immune tolerance characterized by an
autoantibody response to this protein.

LEDGF/p75 Structure and Domain
The LEDGF gene was mapped to chromosome 9p22.2, a region implicated in
cancer [310]. The LEDGF gene encodes 15 exons and 14 introns, where LEDGF/p75 is
encoded by exons 1-15 (530aa) and LEDGF/p52 by exons 1-9 and part of intron 9 [303]
(333aa) (Figure 3a). LEDGF is a nuclear protein that preferentially associates with
condensed chromatin areas and remains tightly bound to chromatids during cell division.
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Figure 3. Schematic representation of the domain structure of LEDGF/p75 and
LEDGF/p52. A) LEDGF/p75 is composed of exons 1-15. p52 shares the same N-terminal
9 exons, with the addition of intron-derived eight amino acids. B) The shared regions of
both proteins contain the PWWP domain, the nuclear localization signal (NLS), the basic
leucine zipper (bLZ) domain overlapping the helix-turn-helix (HTH) region, and an AThook motif. The LEDGF/p52 C-terminal end contains an intron derived 8 amino acid
sequence termed C-terminal tail (CTT) that is not present in LEDGF/p75. The
LEDGF/p75 C-terminal region (absent in p52) contains an integrase binding domain
(IBD).
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Both LEDGF splice variants belong to the hepatoma derived growth factor
(HDGF) family, sharing homology in the N-terminal region where a PWWP domain
(residues 1-98) is found [311-313]. The name of this domain derives from the presence of
the tetrapeptide motif “proline-tryptophan-tryptophan-proline”. Most proteins with
PWWP domains bind DNA and are putative transcription factors. Secondary structure
prediction using PSIPRED program [314] suggested that the PWWP protein is composed
of three beta sheets followed by an alpha helix. In addition, both LEDGF proteins share a
nuclear localization signal (NLS) at residues 148-156, a Tat like sequence within the NLS
region, a basic leucine zipper (bLZ) sequence that overlaps with a helix-turn-helix (HTH)
region in residues 154-175, and two AT-hooks in residues 178-183 and 191-197 (Figure
3b) [315-316]. In general, AT-hooks bind to minor groove of AT rich DNA, and are
thought to co-regulate transcription by modifying the architecture of DNA to enhance the
accessibility of promoters to transcription factors. The tri-partite region, consisting of the
NLS, AT-hooks and charged region 1 (CR1), is sufficient for chromatin binding [316],
while CR2 facilitates LEDGF/p75 binding to supercoiled DNA [317] . LEDGF variants
have little secondary structure, with mostly large random coiled regions which are
implicated in DNA and RNA recognition, modulation of protein binding, and control of
protein lifetime [318]. Similar to high mobility group (HMGA) proteins, LEDGF variants
may be downstream targets that are transcribed or modified specifically to various
environmental influences and interact with proteins or DNA in an interactome,
influencing a diverse array of normal biological processes including growth,
proliferation, differentiation and death [319].
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The C-terminus of LEDGF/p75, absent in LEDGF/p52, contains a region (res
339-442) that shares sequence homology with HDGF-related protein 2 (HRP-2) and has
been defined as the Human immunodeficiency virus-1 (HIV-1) integrase binding domain
(IBD) [320-321]. In addition, this domain overlaps with the epitope recognized by human
anti-LEDGF/p75 autoantibodies [322] and is the only ordered region (res 411-438) in the
C-terminal domain [306]. This region has also been found to interact with
other proteins such as PogZ, JPO2, and menin-MLL (mixed-lineage leukemia) complex
[323-326] and tethers them to the chromatin.
A recent report combined different quantitative fluorescence techniques to
monitor in vivo chromatin interactions of LEDGF/p75 [327]. LEDGF/p75 was observed
to have dynamic interactions with immobile protein/chromatin complexes. It moves
about in nuclei of living cells in a chromatin scanning/hopping mode typical of
transcription factors [328], which most likely is the mechanism used to tether HIV
integrase (IN) to random regions. In line with previous reports in HIV and menin/MLL,
LEDGF/p75 was observed to mediate chromatin tethering of its cargo [329].

LEDGF/p75 and the Cellular Stress Response
LEDGF/p75 was originally thought to be a lens epithelial cell (LEC) growth
factor since its overexpression enhanced the survival and growth rate of mouse LECs,
cos7 cells, human fibroblasts, keratinocytes, and retinal cells [330-331]. In addition,
deprivation of LECs of this protein with anti-LEDGF/p75 antibodies reduced its nuclear
localization and induced cell death [332]. Mice injected with LEDGF protein had better
preserved rods and cones and higher levels of Hsp25 and αB-crystallin compared to
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vehicle-injected mice [333]. Further analysis of LEDGF/p75 revealed that its function
was not that of a growth factor but of a survival protein that protected mammalian cells
from thermal, oxidative and serum stress through the transcriptional activation of stress
proteins such as heat shock protein 27 (Hsp27), αB-crystallin [330-331, 334-336]
antioxidant protein 2/peroxiredoxin 6 (AOP2/Prdx6), alcohol dehydrogenase (ADH)
[302, 337-338], involucrin [339], vascular endothelial growth factor (VEGF-c) [340], and
interleukin-6 ( IL-6) [341].
LEDGF/p75 was reported to recognize stress response elements (STRE) and heat
shock elements (HSE) in promoters of stress proteins [302, 342]. However, further
studies failed to confirm exclusive binding to these sites [316]. Recently, LEDGF/p75
was demonstrated to primarily bind downstream of active transcription units transcription
start site using DamID technology, focusing on the highly annotated ENCODE
(encyclopedia of DNA Elements) region. LEDGF/p75 binding was not restricted to
STRE or HSE in the genome, and correlated with active chromatin markers and RNA
polymerase II binding [343].
Our group has shown that overexpression of LEDGF/p75 protects HepG2 cells
from serum deprivation-induced cell death [312]. However, cleavage fragments of
LEDGF/p75 generated by caspases appeared to enhance cell death, suggesting that
proteolytic cleavage of LEDGF/p75 during apoptosis not only abolishes its survival
activity but may accelerate cell death [312]. We also demonstrated that LEDGF/p52 is
cleaved by caspases to generate a prominent fragment of 38 kDa termed p38 [344].
Transient overexpression of LEDGF/p52 as well as the p38 fragment displayed classical
features of apoptosis in various tumor cell lines [344]. The p38 fragment was found to
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inhibit the transcriptional function of LEDGF/p75 necessary for its stress survival
activity. These results suggested that while LEDGF/p75 acts as a stress survival protein,
its spliced variant p52 has the opposite effect, an inducer of apoptosis that antagonizes
the pro-survival function of LEDGF/p75. Consistent with these findings, we
demonstrated that human cancer cell lines express high levels of LEDGF/p75 but low
levels of p52 [344].
Stable overexpression of LEDGF/p75 in RWPE-2 and PC3 PCa cells conferred
protection to the cytotoxic drug docetaxel but not to caspase-dependent apoptosisinducers, TRAIL and staurosporine (STS), suggesting that LEDGF/p75 might promote
resistance preferentially to oxidant-induced caspase-independent cell death associated
with lysosomal destabilization [345]. LEDGF/p75 also modulates caspase-independent
lysosomal cell death in HeLa and MCF-7 cancer cells, promoting tumorigenic potential
of mouse-bearing HeLa tumors [346].
Recent studies by Huang et al. identified other splice variants of p52 that display
pro-apoptotic activity in Acute myeloid leukemia (AML) blasts [347]. One of these
variants, p52b, is identical to p52 except for an extra 25 amino acid region at the Cterminus due to altered open reading frame. Other low expression variants with gross
deletions in exons 5–8 were detected [347]. LEDGF/p75 and p52b antagonized
daunorubicin- and cAMP-induced apoptosis in human NB4 AML cell line and HEK 293,
whereas LEDGF/p52 splice variants with the deletions had pro-apoptotic effects.
Overexpression of full length LEDGF/p75 protected cells against the pro-apoptotic
effects of the p52 constructs.
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Regulation of LEDGF/p75 Function
The charged domains of LEDGF (comprising of 16% lysines), make it a likely
target of small ubiquitin-like modifier (SUMO) modification. SUMOylation sites mapped
on LEDGF/p75 and p52 include K75, K250, and K254. Another site, K364, is on the Cterminal end present only on LEDGF/p75 and is different from the other lysine residues
in that it is solvent exposed and situated in a typical consensus motif. The cellular
localization of LEDGF/p75, as well as its chromatin binding ability, are not affected by
SUMOylation [348]. However, mutation of K364R impaired LEDGF/p75 SUMOylation,
extended the half life of the protein, and enhanced its transcriptional activity on Hsp27pr
[348]. This is in line with previous reports where SUMOylation of transcriptional
regulators were found to generally increase their transcriptional repressive activites, as
seen in the regulation of genes during interferon response [349-351].
The pro-survival function of LEDGF/p75 appears to be attenuated by
transforming growth factor beta (TGF-β1), a known regulator of apoptosis which downregulates LEDGF/p75 gene transcription and protein expression in human lens epithelial
cells [352]. TGF-beta1 also induced down-regulation of LEDGF/p75, Hsp27, and
alphaB-crystallin promoter activities. This attenuation was proposed to occur through the
TGF-β1 inhibitory element (TIE) on LEDGF/p75 promoter region [353] or through
caspase activation, which cleaves LEDGF/p75 [312]. The role of TGF-β1 as a repressor
of LEDGF/p75 was confirmed in a mouse cell line derived from a Prdx6 knockout model
(Prdx6-/-) [354]. This cell line displayed reduced LEDGF/p75 levels, but had increased
mRNA and protein levels of TGF-β1, thus confirming its role in LEDGF/p75 repression
[354].
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Another protein that attenuates LEDGF/p75 survival activity is the anti-apoptotic
protein Bcl-2 [355]. Initially, Bcl-2 was found to prevent interleukin-3 (IL-3)-dependent
cells from apoptotic death upon withdrawal of the cytokine [356]. Bcl-2 has been shown
to protect a variety of cells against apoptosis induced by serum and growth factor
depletion, as well as gamma irradiation [357-359]. It also protects mammalian cells from
oxidative stress [360-361]. Bcl-2 is involved in the regulation of cell cycle [362],
modulation of cell differentiation [363-364], and regulation of gene expression [355,
365-368]. However, Bcl-2 up-regulation does not protect Burkitt's lymphoma and
lymphoid cell lines from oxidative stress and oxidative stress-induced apoptosis [369370], suggesting that its protective effect is cell line dependent. Rabbit LECs (rLECs)
transfected with Bcl-2 were found to be more susceptible to H2O2-induced apoptosis due
to the down-regulation of αB-crystallin through Bcl-2-mediated attenuation of
LEDGF/p75 transactivation [355]. This attenuation was achieved through activation of
ERK1/2 kinases [371]. Inhibition of the ERK1/2 signaling pathway with pharmacological
inhibitors or dominant-negative mutants abolished Bcl-2 modulation of AP-1 and
LEDGF/p75.

LEDGF/p75 and Cancer
The presence of serum autoantibodies in patients with PCa was first reported in year
1972 [372]. The characterization of autoantibody responses in PCa has led to the
identification and characterization of a number of candidate tumor-associated antigens
(TAA). Among these antigens are 5α-reductase, p53, prostasomes, glucose-regulated
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protein-78kDa (GRP78), MUC1, PARIS-1, p90 and p62 , and several cancer/testis
antigens [373].
Our group reported the presence of autoantibodies to LEDGF/p75 in PCa patients’
sera [374]. In that study by Daniels et al., elevated expression of LEDGFp75 was
observed in PCa cell lines and tumors but not in normal prostate cells or tissue. The
cleavage of overexpressed LEDGF/p75 in dying tumor cells might generate
immunogenic forms of the protein that could be potentially immunostimulatory. Since
anti-LEDGF/p75 autoantibodies are a common finding among ANA-positive individuals
with no obvious symptoms or systemic autoimmune disease, they could be considered
fingerprints or sensors of hidden inflammatory conditions associated with increased
oxidative stress, which could trigger up-regulation and/or activation of LEDGF/p75, and
consequently, loss of immune tolerance to the activated protein.
Up-regulation of LEDGF/p75 has also been reported in breast biopsies [346]. In
addition, significant increase in LEDGF/p75 mRNA was reported in bladder cancers but
not in colon cancer [346]. Recent studies from our group established that this protein is
upregulated (both transcript and protein levels) in several major human cancers,
particularly in PCa (Basu et al., unpublished observations). Analysis of LEDGF/p75
transcript expression in Oncomine cancer gene microarray database revealed significant
upregulation in 15 out of 17 tumor types, including breast, cervix, head and neck, kidney,
skin, and stomach cancer (Basu et al., unpublished observations). Immunohistochemistry
(IHC) analysis of LEDGF/p75 protein expression in tissue microarray (TMA)s from over
35 major types of human cancer detected significant overexpression of LEDGF/p75
protein in prostate, colon, liver, thyroid and uterine tumors.
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Down-regulation of LEDGF/p75 by Hsp70-2 knockdown was observed in HeLa
(cervical cancer), MCF-7 (breast cancer) and U2OS (osteosarcoma) cells. This resulted in
reduced cell proliferation, apoptosis-like chromatin condensation, and destabilization of
lysosomes [285]. Back-complementation of LEDGF/p75 reversed cell death induced by
siRNA knockdown. Addition of pan-caspase inhibitor zVAD-fmk or antiapoptotic
protein Bcl-2 failed to inhibit cell death in both LEDGF/p75 deficient HeLa and MCF-7
cells, suggesting involvement of caspase-independent cell death [285].
LEDGF/p75 has also been implicated in leukemia. The protein was found to be
overexpressed in blasts from chemotherapy-resistance human AML patients [347]. Using
serologic identification of recombinant expressed proteins (SEREX), LEDGF/p75 had
been previously identified as an autoantigen in chronic lymphocytic leukemia (CLL)
[375]. LEDGF/p75 has been also associated with chromosomal translocations in the
t(9;11)(p22;p15) in both adult and pediatric AML and chronic myeloid leukemia (CML)
(32-34), resulting in fusion of the C-terminus of LEDGF/p75 with the N-terminus of the
nucleoprotein 98 (NUP98). The NUP98 gene is involved in 11p15 translocations in both
de novo and therapy related AML as well as T-cell acute lymphoblastic leukemia (ALL)
[376]. NUP98 encodes a component of the nuclear pore complex involved in
nucleocytoplasmic transport as a docking protein [377]. The N-terminus of NUP98
contains 28 FxFG repeats (where x is usually a small residue such as Ser, Gly or Ala),
core sequence motifs known to interact with CREB binding protein (CBP/p300) and act
as transactivation domains [378] and has been reported to be rearranged in chromosomal
translocations in patients with myelodysplastic syndromes, AML and T-cell acute
lymphoblastic leukemia [376, 379-382]. In leukemias expressing NUP98 fusion proteins,
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transcriptional regulation is altered, correlating to poor prognosis as in the case of
overexpression of HoxA9 in AML patients [383]. Although the role of the NUP98LEDGF/p75 fusion in AML patients is unknown, it is likely that this fusion might play a
role in formation of multimeric complexes or facilitate interaction with other
transcription factors or cofactors, thereby enhancing the transcriptional and pro-survival
activities of LEDGF/p75 [384].
LEDGF/p75 is also a crucial cofactor required for promoting leukemic transformation
or suppressing tumorigenesis in the endocrine lineage (multiple endocrine neoplasia type
1) by interacting with MLL/menin complexes [323] (to be discussed in more detail later).

LEDGF and its Interacting Proteins
HIV-1 IN
LEDGF/p75 is a cellular interaction partner of HIV-1 IN [385-387].
Recombinant LEDGF/p75 added to in vitro HIV based integrase assay enhanced
recombinant HIV-1 IN strand transfer activity [385], while its knockdown of endogenous
LEDGF/p75 abolished nuclear localization of HIV-1 IN together with its association with
chromosomes [387-388]. The presence of LEDGF/p75 was also shown in the preintegration complex (PIC) [389].
Interaction between LEDGF/p75 and HIV-1 IN is through LEDGF/p75’s IBD
domain (aa 347-429) located on its C-terminus [390-391]. NMR studies show a
symmetrical complex containing a pair of IN tetramers and two subunits of LEDGF/p75
[390]. Deletion of both PWWP and AT hook domains depleted chromatin-association of
LEDGF/p75, leading to defective HIV-1 replication [390]. Depletion of LEDGF/p75
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resulted in a redistribution of HIV-1 integration sites from its characteristic distribution in
transcription units (TUs) outside the promoter regions to a more aspecific distribution
[392-393]. LEDGF/p75 also protects HIV-1 IN from proteosomal degradation in the cell
[388, 394].
Due to LEDGF/p75’s function in tethering HIV1-IN to the chromatin, a rigorous
search for potential proteins that interfere with its HIV-IN binding has been launched,
resulting in the identification of the proteins discussed below.

JPO2
JPO2, also known as RAM2, represses transcription of human monoamine
oxidase (MAO) A through binding to three repetitive Sp1 sites in the promoter [395].
JPO2 potentiates c-Myc transforming activity and complements a transformationdefective Myc mutant [396]. JPO2 is closely related to JPO1, a Myc transcriptional target
encoded by a Myc responsive gene [397]. It contains a PEST region (peptide sequence
rich in proline (P), glutamic acid (E), serine (S), and threonine (T)) in its N-terminal
region (res 29-54), a C-terminal RING-ringer-like zinc-binding motif (res 349-425), a
putative leucine zipper (res 213-235), and a putative nuclear localization signal (res 301318) [395]. Similar to HIV-1 IN, JPO2 is protected from degradation by LEDGF/p75,
and is tethered to the chromatin [325]. It competes with IN for LEDGF/p75 binding
[324,325]. Over-expression of JPO2 resulted in slight inhibition of HIV-1 replication but
activated transcription from the HIV-1 LTR (Long terminal repeats) [325].
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Menin/MLL complex
Menin is a tumor suppressor implicated in cancer pathogenesis and transcriptional
regulation as an integral component of the MLL histone methyltransferase (HMT)
complex. LEDGF/p75 binding to the MLL complex is mediated by menin, which tethers
the complex onto the chromatin, leading to transcription and leukemic transformation
[323]. Menin is a product of the MEN1 gene, and its functions are cell type, cell cycle,
and interaction dependent [398]. Its loss of function results in multiple endocrine
neoplasia type 1 (MEN1) [399], a syndrome characterized by a triad for parathyroid,
enteropancreadtic endocrine, and anterior pituitary gland tumors. Double knock-out of
Men1 in the mouse is embryonic lethal [400], and no homozygous mutation has ever
been detected in humans. In addition, it participates in dynamic regulation of pancreatic
cell proliferation in response to normal physiologic demands during pregnancy [401].
Like LEDGF/p75, menin regulates transcription of heat shock proteins in fruit flies
[402], and associates with RNA pol II [403] and Fanconi anemia group D2 protein
(FANCD2), a protein involved in repair of DNA damage [404]. Notably, Menin, c-myc
and Ski-interacting protein (SKIP) act together to promote HIV-1 Tat transactivation
[405], suggesting that LEDGF/p75 interacts in a complex that works together for multiple
functions, either in virus replication, or stress-induced transactivation. Along this line,
LEDGF/p75 interactome would need other proteins to tightly regulate their transcription
modulation fucntion.

PogZ
Using yeast-two hybrid screening, PogZ (pogo transposable element derived protein
with zinc finger) was identified to interact with the C-terminus of LEDGF/p75 [324].
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PogZ was previously identified as a potential interaction partner of the transcription
factor Sp1 in a yeast-two-hybrid screen [406]. However, its cellular function was
unknown. In silico analysis revealed that PogZ contains a six zinc-finger array in its Nterminus, with a characteristic catalytic site composed of two or three aspartic acid and/or
glutamic acid residues with a specific spatial arrangement to allow coordination of Mg2+
cations (DDE (Asp, Asp,Glu motif)) domain) and a helix-turn-helix domain in its Cterminal end. Its DDE domain is essential for DNA strand cleavage, transfer and ligation
[407]. PSI-BLAST algorithm uncovered pogZ sequence homology with Tigger Derived
(TIGD) transposases, a domesticated transposase related to the DNA-transposases. PogZ
does not restrict HIV-1 replication, and was efficiently displaced by HIV-1 integrase in
competition assays [324].

Cdc7:ASK
Phosphorylation of cell division cycle 7 bound to activator of S phase kinase
(Cdc7:ASK) is essential for interaction with its LEDGF/p75 [408]. Besides stimulating
Cdc7:ASK kinase activity in vitro, LEDGF/p75 also enhances phosphorylation of MCM2
at Ser 53, the major target of Cdc7 phosphorylation [408]. Cdc7 is involved in meiotic
recombination[409] and in replication-dependent DNA repair [410]. ASK expression is
cell-cycle dependent [411], while Cdc7 protein levels remain stable throughout the cell
cycle [412], with oscillating kinase activity depending on the abundance of its regulatory
subunit [411]. Together with S-phase cyclin-dependent kinase, Cdc7 activates individual
pre-replication complexes (pre-RCs) assembled at replication origins during G1. The
Mini Chromosome Maintenance (MCM) complex is the major target of Cdc7 activity in
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mammalian cells [413]. Chromatin-bound Mcm2 is phosphorylated by Cdc7 at the G1-S
transition, and is required for initiation of DNA replication [414]. Furthermore, Cdc7
stimulates additional replication factors (Cdc45 and GINS (Go, Ichi, Ni and San)
complex) associated with formation of an active helicase [415].
The association of LEDGF/p75 with JPO2, menin/MLL complex, CDC7-ASK
suggests that LEDGF/p75 functions as a general adaptor between chromatin and proteins
or nucleic-acid protein complexes that must be brought into the proximity of chromatin to
exert their function (transcription, viral integration, etc.). It is possible that bridging
proteins like JPO2 may facilitate the assembly of LEDGF/p75 chromatin association
complexes.

MeCP2
Our efforts to identify interacting transcription factors of LEDGF/p75 led to the
detection of methyl CpG binding protein 2 (MeCP2) (discussed in detail in Chapter two).
MeCP2 is important for PCa growth and can overecome growth arrest induced by
androgen receptor antagonist [416-417]. Furthermore, MeCP2 mRNA levels correlated
with estrogen-receptor status in breast cancer specimens [418]. MeCP2 was the first
member of its family discovered by Alan Bird’s group in their effort to identify proteins
bound to methylated DNA [419]. Its methyl CpG binding domain (MBD) is shared with
its other family members MBD1-4 [420]. The MBD forms a wedge-shaped structure
composed of a β-sheet superimposed over an α-helix and loop, which allows for selective
recognition of methylated CpG dinucleotides [421]. It represses transcription through
association with histone deacetylase complexes (HDACs) or through chromatin
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compaction at its TRD domain (Transcription repression domain) [420]. Defective
MeCP2 causes Rett syndrome, a rare X-linked neurodevelopmental disorder [422]. Since
most studies on MeCP2 have been performed in neurons, it is in our interest to study the
interaction of MeCP2 with LEDGF/p75 in PCa.

Purpose and Significance of this Dissertation
The purpose of this dissertation was to study the interactions of both LEDGF/p75
and p52 with other transcription factors to examine their modulation of genes under
oxidative stress environments. The upregulation of the Hsp27 promoter by LEDGF/p75
led to the hypothesis that LEDGF/p75 interacts with transcription factors to activate
stress and antioxidant genes in order to protect cancer cells from stress-induced cell
death
To gain insight into the mechanism by which LEDGF/p75 confers this resistance
we pursued the following aims:
1. To investigate the interaction of LEDGF/p75 and p52 with MeCP2.
2. To explore modulation of stress proteins by the LEDGF-MeCP2 interaction.
3. To examine if this interaction protects PCa cells from stress-induced death.
Our studies showed that LEDGF/p75 and p52 interacts with MeCP2 both in vitro
and in cellular assays. In addition, we showed that MeCP2 increased transactivation of
the Hsp27 promoter (Hsp27pr). Furthermore, we showed novel binding of both proteins
to the Hsp27pr region. Depletion of LEDGF/p75 resulted in robust upregulation of
Hsp27pr in the presence of MeCP2 in U2OS cells. On the other hand, synergistic effects
of both proteins were seen with thiol-disulfide oxidoreductase of the endoplasmic
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reticulum promoter (ERp57pr) and IGFBP5pr in PC3 PCa cells. This suggests that
LEDGF and MeCP2 interaction may have different functional consequences that are
promoter and cell type specific.
In other experiments, LEDGF/p75 overexpression was shown to protect PCa cells
against tert-butyl hydrogen peroxide (TBHP)-induced cell death. However, LEDGF/p75
did not protect PCa cells against classical inducers of apoptosis such as TRAIL and
staurosporine (STS), suggesting that this protein promotes resistance to inducers of nonapoptotic cell death. The role of MeCP2 in PCa chemoresistance remains to be
determined in future work.
The studies described in this dissertation will provide insights into the interactions
between LEDGF/p75 and other transcription factors. These studies are highly significant
because they will contribute to a better understanding of protein-protein interactions in
stress gene transcription regulation within the context of chemoresistance. We anticipate
that this will lead to the development of innovative molecular targeting strategies that
would act synergistically with traditional chemotherapeutic agents in PCa.
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Abstract
The lens epithelium derived growth factor p75 (LEDGF/p75) is a transcription coactivator that promotes resistance to oxidative stress- and chemotherapy-induced cell
death. LEDGF/p75 is also known as the dense fine speckles autoantigen of 70 kD
(DFS70), and has been implicated in cancer, inflammation, autoimmunity, and HIVAIDS. To gain insights into the mechanisms by which LEDGF/p75 protects cancer cells
against stress, we initiated an analysis of its interactions with other transcription factors
and the influence of these interactions on stress gene activation. We report here that both
LEDGF/p75 and its short splice variant LEDGF/p52 interact with MeCP2, a methylationassociated transcriptional modulator, in vitro and in human cancer cells. These
interactions were established by several complementary approaches: transcription factor
protein arrays, pull down and AlphaScreen® assays, co-immunoprecipitation, and
nuclear co-localization by confocal microscopy. MeCP2 was found to interact with the
N-terminal region shared by LEDGF/p75 and p52, particularly with the PWWP-CR1
domain. Like LEDGF/p75, MeCP2 bound to and transactivated the Hsp27 promoter
(Hsp27pr). Co-expression of LEDGF/p75 and MeCP2 significantly enhanced MeCP2induced Hsp27pr transactivation in PC3 prostate cancer cells but not in U2OS bone cells.
LEDGF/p52 repressed MeCP2-induced Hsp27pr activity. Interestingly, siRNA-induced
silencing of LEDGF/p75 in both cell lines dramatically elevated MeCP2-mediated
Hsp27pr transactivation, suggesting that LEDGF/p75 regulates MeCP2 transcriptional
activity. Our results suggest that the LEDGF/p75-MeCP2 interaction differentially
influences Hsp27pr activation depending on the intracellular levels of these proteins and
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the cell context. These findings are of significance in understanding the contribution of
this interaction to the activation of stress survival genes.

Introduction
LEDGF/p75 is a stress response protein with relevance to cancer, autoimmunity,
inflammation, eye disease, and replication of the human immunodeficiency virus type 1
(HIV-1). LEDGF/p75 and its splice variant p52 are derived from the PSIP1 gene and
were originally identified as transcription coactivators that interact with the RNA
polymerase II transcription complex (1). LEDGF/p75 is also known as the dense fine
speckled autoantigen of 70 kD (DFS70), which is targeted by autoantibodies in various
human inflammatory conditions (2). Although initially proposed to be a growth factor
for lens epithelial cells (3), subsequent studies revealed that LEDGF/p75 is a stress
survival protein that protects against oxidative stress-induced cellular damage and death
(4,5). As a key cellular co-factor for HIV-1 replication, LEDGF/p75 binds the HIV-1
integrase (IN) through its C-terminal integrase-binding domain (IBD) and tethers it to the
chromatin, facilitating lentiviral integration to transcriptionally active regions of the host
genome (6-8).
LEDGF/p75 is emerging as an oncoprotein in various human cancers. It is
targeted by autoantibodies in patients with prostate cancer, and is overexpressed in
prostate tumors and other human malignancies, including chemotherapy-resistant human
acute myelogenic leukemia (9-11). In addition, it can be found as a fusion protein with
NUP58 in leukemia patients (12). Its overexpression in tumor cells attenuates lysosomal
cell death induced by stressors that trigger oxidative stress (e.g. certain chemotherapeutic
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drugs, tumor necrosis factor, and serum starvation) (5,10,11,13). LEDGF/p75 also
enhanced the tumorigenic potential of HeLa cells in xenograft models (10).
The mechanisms by which LEDGF/p75 promotes cell survival under stress are
still unclear, although available evidence indicates that this protein transcriptionally
activates genes encoding protective proteins such as heat shock protein 27 (Hsp27), αBcrystallin, peroxiredoxin 6 (PRDX6), and vascular endothelial growth factor c (VEGF-c)
(14-16). Presumably, LEDGF/p75 transactivates these stress genes by binding to heat
shock elements (HSE; nGAAn) and stress elements (STRE; A/TGGGGA/T) in their
promoter regions (14-16). In leukemia cells, LEDGF/p75 interacts with oncogenic
transcription complexes, such as the menin/MLL-HMT (mixed lineage leukemia histone
methyltransferase) complex, to transactivate cancer-associated genes and facilitate
leukemic transformation (17).
The transcriptional and pro-survival activities of LEDGF/p75 are attenuated by
TGF-β1 (18), Bcl-2 (19), SUMOylation (20), and caspase-mediated cleavage (5). The
pro-survival function of LEDGF/p75 is also regulated by alternative splicing since
ectopic expression of its splice variant p52 antagonizes its transcriptional activity and
induces apoptosis in cancer cells (21). LEDGF/p75 and p52 share N-terminal amino
acids (aa 1-325); however, p52 has an intron-derived C-terminal tail (CTT, aa 326-333)
implicated in its pro-apoptotic activity (1,21). The N-terminal region shared by both
proteins contains a PWWP domain (aa 1-93), an entity implicated in chromatin binding,
transcriptional repression, and methylation (22-24). The N-terminal region also has a
positively charged domain (CR1) immediately after the PWWP domain that is followed
by a nuclear localization signal (NLS) and two AT-hook (ATH) sequences that cooperate
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with the PWWP domain for chromatin binding (25,26). A second charged region (CR2),
also designated the supercoiled-DNA recognition domain (SRD) (aa 200-336), facilitates
LEDGF/p75 binding to active transcription sites (27). The C-terminus of LEDGF/p75
(aa 347-429) encompasses both the IBD and the autoepitope recognized by human antiLEDGF/p75 autoantibodies (8,28). This region is involved in protein-protein interactions
and binding to HSE in promoter regions (17,29-32). Both the N- and C-terminal regions
of LEDGF/p75 contribute to its transcription and stress survival functions (5,32).
Understanding the mechanisms by which LEDGF/p75 promotes tumor cell
resistance to cell death and chemotherapy requires detailed knowledge of its cellular
functions, particularly its interactions with other cancer-associated proteins, and its target
genes. To date only a few cellular interacting partners of LEDGF/p75 have been
identified. These include the PC4 transcription factor, menin/MLL, the Cdc7 activator of
S-phase kinase (ASK), the pogZ (pogo transposable element derived protein with zinc
finger) transposase, and the myc-interacting protein JPO2 (17,29-31). Using
transcription factor protein arrays we identified several candidate interacting partners of
LEDGF/p75. Among these, methyl-CpG binding protein 2 (MeCP2) was of particular
interest because, like LEDGF/p75, it has been linked to prostate cancer progression
(33,34). MeCP2 belongs to a family of methylated CpG binding proteins, and is mutated
in Rett syndrome (35). MeCP2 contains an N-terminal methyl CpG binding protein
(MBD) domain and a C-terminal transcriptional repression domain (TRD), and
depending on its interacting partners either represses or activates gene transcription
(35,36). In this study we characterized the interaction between LEDGF/p75 and MeCP2

80

in vitro and in human cancer cells. We provide evidence that the N-terminal region of
LEDGF/p75 binds to MeCP2 and influences its transcriptional function.

Materials and Methods
Cell Lines, Antibodies and Plasmids
U2OS, PC3 and 293T cells were obtained from the American Type Culture
Collection and cultured in McCoy’s 5A medium or RPMI 1640 (Gibco), supplemented
with 2 mM L-glutamine and penicillin/streptomycin, and 10% fetal bovine serum. PC3
cells stably expressing LEDGF/p75 (13), were grown in RPMI 1640, and supplemented
with 10% (v/v) fetal bovine serum (FBS), 20 g/l of gentamicin, and 0.5 mg/ml of
geneticin. Cells were grown with 5% CO2 at 37°C.
The following antibodies were used: mouse monoclonals anti LEDGF/p75-p52
(BD Biosciences), anti-β-actin (Sigma); rabbit polyclonals anti-LEDGF/p75 (Bethyl
Laboratories), anti-MeCP2 (ProteinTech Group), anti-HA (Santa Cruz Biotechnology),
anti-eGFP (produced in Z. Debyser’s laboratory); goat polyclonals anti-eGFP (produced
in Z. Debyser’s laboratory), anti-GFP (Santa Cruz Biotechnology), anti-GST (Pharmacia
Biotech), anti-Flag-HRP (Sigma) and rat monoclonal horseradish peroxidase (HRP)conjugated anti-HA (Roche Diagnostics). Human antibodies to LEDGF/p75 were a gift
from Dr. Eng M. Tan (Scripps Research Institute, La Jolla, CA).
Plasmid pET28a-dfs70 encoding His-LEDGF/p75 was a kind gift from Dr.
Edward Chan (University of Florida, Gainesville). Plasmids pDEST-GST-MeCP2 and
pcDNA-Flag-MeCP2 were a kind gift from Dr. Adrian Bird (University of Edinburgh,
UK). Plasmids pKB6H-p52, pMal™-p2x-BRD4-Ct, and p-eGFP-BRD4-Ct were
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generated in Z. Debyser’s laboratory. Plasmids pCruzHA-LEDGF/p75, pCruzHA-p52,
and pGL3-Hsp27pr-Luc were generated as described (21). Plasmid eGFP-p52 was cloned
by replacing the LEDGF/p75 cDNA in p-eGFP-LEDGF/p75 vector with the LEDGF/p52
cDNA at XhoI and BamHI restriction sites.

Purification of Recombinant LEDGF/p75, p52 and MeCP2
GST-tagged MeCP2 was produced from pDEST-MeCP2 in E. coli BL21 grown
in the presence of sorbitol and betaine. Expression was induced in lysogeny broth (LB)
medium at 37°C by addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG).
Cells harvested 3 h after induction were lysed by sonication in core buffer (50 mM Tris
HCl , 0.5 M NaCl, pH7.5, 10 mM EDTA, 10 mM EGTA, 1% Triton X-100, and 20
g/ml lysozyme). The fusion protein, captured on glutathione agarose (Sigma) or
glutathione sepharose beads (GE Healthcare Life Sciences), was eluted with 20 mM
glutathione in core buffer. His-tagged LEDGF/p75 and p52 were expressed from
pET28a-dfs70 and pKB6H52 in E. coli BL21, respectively. Expression was induced with
1 mM and 3 mM IPTG, respectively, at 37°C for 3 h. Bacteria were lysed by sonication
in B-PER® bacterial protein extraction reagent (Thermo Scientific). The recombinant
proteins were captured on nickel columns (Novagen) or TALON® His-Tag Purification
Resins (Clontech), and washed with 20 mM HEPES, 0.5 M NaCl, 2 mM KCl, 1% NP-40,
and 5 mM imidazole. Proteins were eluted with 20 mM HEPES, 137 mM NaCl, 2 mM
KCl, 300 mM imidazole, and dialyzed using D-tube™ dialyzer (Novagen).

82

Transcription Factor Arrays
Two transcription factor protein arrays that were commercially available at the
time we initiated these studies, Active Protein ArrayTM (Active Motif), and TranSignal
Protein Arrays I-III (Panomics), were used for identifying interacting partners of
LEDGF/p75 following the manufacturer’s instructions. These arrays contained a total of
170 transcription factors and co-activators, as well as RNA polymerase II, spotted on
membranes in duplicates or triplicates. Briefly, membranes were blocked with 5% milk
in tris-buffered saline tween-20 (TBS-T) buffer for 1 h. Recombinant His-LEDGF/p75
was incubated overnight with the membranes and after washes with TBS-T, the
membranes were probed with human anti-LEDGF/p75 autoantibody for 2 h. Following
washes with TBS-T, the membranes were incubated with HRP-conjugated secondary
antibodies, and protein interaction signals were detected by chemiluminescence
(Amersham).

Pull Down Assays
GST or GST-MeCP2 proteins bound to glutathione beads were blocked in HEPES
buffer (20 mM HEPES, pH 7.4, 2 mM DTT, 137 mM NaCl, 2 mM KCl, 5% glycerol)
with 0.1% bovine serum albumin at 4°C for 1 h. His-LEDGF/p75 or His-p52 were then
incubated with the beads at 4°C for 1 h in HEPES buffer. The beads were then collected
by centrifugation at 5,000 rpm for 30 seconds at 4°C, the supernatant was discharged, and
the beads were washed two times with 1 ml of HEPES buffer + 0.1% NP-40 followed by
HEPES buffer + 0.5% NP-40 + 0.5 M NaCl. Bound proteins were eluted in SDS-PAGE
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sample buffer, separated by SDS-PAGE (10% Bis-Tris gel) and detected by
immunoblotting.

Analysis of Protein-protein Interactions by AlphaScreen® Assay
The AlphaScreen® assay was performed according to the manufacturer’s protocol
(Perkin Elmer). Briefly, reactions were performed in 25 l final volume in 384-well
OptiwellTM microtiter plates. The reaction buffer contained 25 mM Tris-HCl pH 7.4, 150
mM NaCl, 1 mM MgCl2, 0.1% Tween 20, 0.1% BSA. Varying concentrations of GSTMeCP2 in bacterial lysate and purified Flag-LEDGF/p75 were incubated in 15 l
reaction volume at 4°C for 1 h. The concentration of GST-MeCP2 in the lysates was
estimated using BSA standards on SDS-PAGE gels stained with Coomassie Blue. Equal
volume of bacterial lysate not expressing GST-MeCP2 was used as negative control.
Subsequently, 5 l of the diluted donor (glutathione) and acceptor (Flag) beads were
added. After incubation for 1 h in the dark, light emission was measured in the
EnVision® reader (Perkin Elmer) and analyzed using the EnVision® manager software.

Transient and Stable Transfection
293T cells were transfected in 10 cm3 plates by polyethyleneimine (PEI)
transfection. Ten g of plasmid DNA were used to transiently transfect cells at >50%
confluency. U2OS and PC3 cells were transfected using TransIt® 2020 (Mirus)
transfection reagent. Transfected cells were grown for 24-48 h before analysis. Stable
PC3 clones overexpressing LEDGF/p75 were generated by transfecting cells with
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pcDNA-LEDGF/p75, or empty pcDNA vector for controls, and growing them in
selection media containing geneticin (Calbiochem) as described (13).

Co-immunoprecipitation
U2OS cells were collected 48 h post transfection and lysed in RIPA buffer (Santa
Cruz Biotechnology). Antibodies were incubated with cell lysates for 1 h before protein
A/G+ agarose beads (Santa Cruz Biotechnology) were added. The beads were collected
by centrifugation and washed 3 times with core buffer (50 mM Tris pH 7.5, 300 mM
NaCl, 1 mM MgCl2, 5% glycerol, complete protease inhibitor EDTA free (Roche) and
0.1% NP-40. U2OS cells overexpressing Flag-MeCP2 and eGFP constructs were
incubated with Flag-agarose beads. 293T cells were transiently transfected with p-eGFPLEDGF/p75 and pcDNA-Flag-MeCP2. Whole cell lysates were collected 24 h post
transfection and lysed in core buffer with 1% Triton X-100. Antibody against GFP was
incubated with cell lysate overnight before protein G sepharose beads (GE Healthcare)
were added. Immunoprecipitated proteins were separated by SDS-PAGE and detected by
immunoblotting using appropriate antibodies.

Confocal Microscopy
Transfected cells were fixed with 4% formaldehyde and permeabilized with 0.5%
Triton X-100. Cells were washed with PBS after incubation with anti-MeCP2 antibodies
and mounted with medium containing 4’,6-diamidino-2-phenylindole (DAPI)
(Vectashield). Confocal microscopy was performed using Zeiss LSM7 confocal
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fluorescence microscope with 63x oil immersion objective and appropriate filters. Images
were analyzed using ImageJ software.

Luciferase-based Transcription Reporter Assays
Hsp27pr luciferase transcription reporter assays were performed as described
previously (21). Briefly, cells were co-transfected with plasmids encoding the proteins of
interest or empty vector, and pGL3-Hsp27pr. At 48 h post-transfection, cells were lysed
and luciferase assays were performed using the Luciferase Assay System (Promega).
Relative light units were obtained in a MicroLumatPlus Lb 96V luminometer (Berthold
Tech) and luciferase values were normalized to protein concentration of lysates from
cells co-transfected with the empty vectors and pGL3-Hsp27pr. Student’s’ t test analysis
was performed using Microsoft Excel. Experiments were repeated at least three times.

LEDGF/p75 Knockdown by RNA Interference
Transient knockdown of LEDGF/p75 was carried out using synthetic siRNA
oligos as described previously (37). The siLEDGF/p75 sequence corresponded to
nucleotides 1340-1360 (5′- AGACAGCAUGAGGAAGCGAdTdT-3′) with respect to the
first nucleotide of the start codon of the LEDGF/p75 open reading frame. Ambion
Silencer® Negative Control siRNA #1 was used as scrambled control. siRNAs were
transfected into U2OS cells using siQuest (Mirus). LEDGF/p75 knockdown was verified
by immunoblotting.
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Chromatin Immunoprecipitation Assays
U2OS cells were fixed in 1% formaldehyde for 10 minutes and subjected to
chromatin immunoprecipitation (ChIP) assay using ChIP-IT Express Enzymatic kit
(Active Motif, Carlsbad). Anti-LEDGF/p75 antibodies (A300-848A, Bethyl), antiMeCP2 antibodies (07-013, Millipore) and rabbit IgG (Santa Cruz Biotechnology) were
used to immunoprecipitate protein-chromatin complexes. PCR was performed using
primers to amplify Hsp27 promoter: set A forward 5'- CGC TTA AGC ACC AGG GCC
GG -3 and reverse 5'- CCG GCC CTG GTG CTT AAG CG -3’; set B forward 5'CTGGGCTCAAGCACCAGACTC -3' and reverse 5'CAAATGAATTCGAGAGCGCGACGC-3'; set C: forward 5’CAGGGTTTTGCTCTGTAG CC-3’ and reverse 5’CCACACGCGTGTGAGATAGAATGTG-3’; set D: forward 5’CTCTGCCTTCTGGGGTTCAAG-3’ and reverse 5’-TTGAACCCCGGTGAGTAGAG3’.

Results
Identification of MeCP2 as a Candidate Interacting Partner of
LEDGF/p75
We hypothesized that LEDGF/p75 interacts with other transcription factors to
transactivate stress genes and promote tumor cell survival in the presence of stress. In
order to identify novel cellular interacting partners of LEDGF/p75, we screened 170
different transcription factors for LEDGF/p75 binding using transcription factor protein
arrays (Panomics and Active Motif). Purified recombinant His-tagged LEDGF/p75 (Fig.
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1A) was incubated with recombinant transcription factors spotted on membranes, and
protein-protein interactions were identified using a specific human autoimmune serum
against LEDGF/p75 (Fig. 4B), followed by signal detection with chemiluminescence
(Fig. 4C). We detected moderate to strong protein-protein interaction signals with 17
different transcription factors, with the strongest reactivity corresponding to the
LEDGF/p75-MeCP2 interaction (Fig. 4C). One array (Active Motif) yielded strong
signals with transcription factor PC4 and RNA polymerase II subunits (data not shown),
consistent with the report that LEDGF/p75 co-purifies with these proteins (1).
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Figure 4. Identification of candidate interacting partners of LEDGF/p75 using
transcription factor protein arrays. A) Coomassie blue stained SDS-PAGE gel showing
purified His-LEDGF/p75. E. coli BL21 was transformed with pET28a-dfs70 encoding
His-LEDGF/p75 and induced with IPTG. Lysate was passed through a nickel column to
purify His-LEDGF/p75. B) Immunoblot showing the specificity of the human
autoantibody against LEDGF/p75 used as detection reagent in the transcription factor
protein arrays. The autoantibody reacts specifically with LEDGF/p75 in a PC3 prostate
cancer cell lysate.
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C

Figure 4. Identification of candidate interacting partners of LEDGF/p75 using
transcription factor protein arrays. C) Transcription factor arrays were used to identify
candidate interacting transcription factors of LEDGF/p75. Purified His-LEDGF/p75 was
incubated with transcription factors spotted on membranes. Protein interactions were
detected with human anti-LEDGF/p75 autoantibody and chemiluminescence. A section
of the transcription factor array membrane containing MeCP2 is showed.
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LEDGF/p75 Interacts with MeCP2 in vitro
To confirm the interaction between LEDGF/p75 and MeCP2 in vitro, pull-down
experiments were performed using recombinant proteins. Beads with bound GST-MeCP2
or GST were incubated with His-LEDGF/p75, and interactions were detected by
immunoblotting using anti-GST antibody. LEDGF/p75 was pulled down with GSTMeCP2 but not with GST (Fig. 5A). An irrelevant protein, His-FADD (Fas-associated
protein with death domain), served as negative control.
A protein-protein interaction assay using the AlphaScreen® technology (PerkinElmer) was used for additional confirmation of the LEDGF/p75-MeCP2 interaction in
vitro. To prevent false positive signals due to rapid degradation of purified recombinant
GST-MeCP2, we used GST-MeCP2 induced in the bacterial lysate. Enhanced bacterial
expression of GST-MeCP2 was attained in the presence of sorbitol and betaine. Cross
titration of increasing concentrations of recombinant Flag-LEDGF/p75 and GST-MeCP2
demonstrated binding between both proteins over a wide range of concentrations (Fig
5B). Optimum binding was observed between 11 nM LEDGF/p75 and estimated 1 nM
GST-MeCP2 (Fig 5C).
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Figure 5. LEDGF/p75 interacts with MeCP2 in vitro. A) Pull down assays with HisLEDGF/p75 and GST-MeCP2. Recombinant His-LEDGF/p75 was incubated with GST
or GST-MeCP2 bound to glutathione beads, and pulled down proteins were analyzed by
immunoblotting using antibodies specific for GST or LEDGF/p75. His-FADD was used
as irrelevant control. Protein input was determined by immunoblotting of whole cell
extracts. *Denotes degraded GST-MeCP2.
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Figure 5. LEDGF/p75 interacts with MeCP2 in vitro. B) Cross titration for FlagLEDGF/p75 and GST-MeCP2 interaction as measured by AlphaScreen® assay.
Interaction was measured at different concentrations of Flag-LEDGF/p75 as indicated on
the vertical legend, and GST-MeCP2 as indicated on the X-axis. The experiment was
performed in triplicate. C) An estimated 1 nM MeCP2 was sufficient to interact with 11
nM LEDGF/p75. E.coli BL21 lysate not expressing GST-MeCP2 was used as a negative
control. Data is representative of three independent measurements.
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LEDGF/p75 Interacts With MeCP2 in a Cellular System
The LEDGF/p75-MeCP2 interaction was confirmed in a cellular system by coimmunoprecipitation (co-IP) assays. Flag-MeCP2 and different eGFP-LEDGF/p75
constructs were co-transfected in 293T cells (for high transfection efficiency). Expressed
proteins were then immunoprecipitated with anti-GFP antibody and pulled down by
protein G agarose beads. Immunoprecipitated proteins were analyzed by immunoblotting
with antibodies against eGFP and Flag tags. Immunoblotting analysis showed MeCP2
interaction with eGFP-LEDGF/p75, but not with eGFP-HIV-IN or the irrelevant protein
eGFP-BRD4-Ct (carboxyl terminal fragment of the bromodomain containing protein 4)
(Fig 6A). To verify that LEDGF/p75 and MeCP2 interact endogenously in cancer cells,
co-IP experiments were performed using U2OS osteosarcoma cells, which express high
endogenous levels of LEDGF/p75 (21). U2OS cell lysates were incubated with antibody
against LEDGF/p75, and the immunoprecipitated proteins were detected by
immunoblotting. Endogenous MeCP2 was detected in immunoprecipitates of endogenous
LEDGF/p75 but not with IgG control (Fig 6B). The LEDGF/p75-MeCP2 interaction was
also confirmed by reciprocal co-IP and immunoblotting in PC3 prostate cancer cells (data
not shown).
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Figure 6. Co-immunoprecipitation of LEDGF/p75 and MeCP2. A) 293T cells cotransfected with Flag-MeCP2 and eGFP-LEDGF/p75, eGFP-HIV-IN, or eGFP-BRD4-Ct
expression constructs were lysed 24 h post transfection. Proteins immunoprecipitated (IP)
with antibody against GFP were resolved by SDS-PAGE and detected by
immunoblotting using anti-GFP and anti-Flag antibodies. B) U2OS cell extracts were
immunoprecipitated with mouse monoclonal anti-LEDGF/p75 antibody. Proteins were
detected by immunoblotting with rabbit anti-LEDGF/p75 and anti-MeCP2 antibodies.
*Denotes degraded MeCP2. Protein input was determined by immunoblotting of whole
cell extracts.
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Confocal microscopy analysis was performed to examine the intracellular colocalization of LEDGF/p75 and MeCP2. U2OS cells were transiently transfected with
plasmids encoding HcRed-LEDGF/p75 and Flag-MeCP2. Both recombinant proteins
displayed a distinctive nuclear speckled pattern and co-localized in the nucleus (Fig. 6C).
Co-localization was also observed with co-expression of eGFP-LEDGF/p75 and FlagMeCP2 (data not shown). Both proteins co-localized with DAPI-stained chromatin
regions.
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Figure 6. Nuclear co-localization of LEDGF/p75 and MeCP2. C) U2OS cells were
transiently co-transfected with pcDNA-Flag-MeCP2 and pHcRed-LEDGF/p75.
Ectopically expressed MeCP2 was detected 48 h post-transfection using anti-Flag
antibodies and visualized with FITC-labeled secondary antibody. Nuclei were stained
with DAPI, and fluorescent signals were analyzed by confocal microscopy.
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The LEDGF/p75 Splice Variant p52 also Interacts with MeCP2
As mentioned above, LEDGF/p75 and its short splice variant p52 share their N
terminal region, which contains the PWWP domain, CR1 and CR2, NLS, and AT-hooks
that collectively facilitate DNA binding (Fig. 7A) [38, 39]. To determine if MeCP2 also
binds to p52 we performed pull-down assays in which recombinant His-p52 was
incubated with GST or GST-MeCP2 beads. Immunoblotting analysis showed that Hisp52 was pulled-down by GST-MeCP2 but not by GST (Fig 7B). Confocal microscopy
showed partial co-localization of HcRed-p52 with Flag-MeCP2 in nuclei of U2OS cells
co-transfected with plasmids encoding these tagged proteins (Fig 7C). Taken together,
these results indicated that p52 also interacts with MeCP2. Since p52 lacks the Cterminal portion of LEDGF/p75, the results also suggested that MeCP2 interacts with the
N-terminal portion of LEDGF/p75.

The N-terminal Region of LEDGF/p75 Mediates the Interaction with
MeCP2
Since LEDGF/p75 and p52 share the same N-terminal region (aa 1-325), we
sought to map the minimal interacting region of these proteins with MeCP2. To
accomplish this, deletion constructs comprising different regions of the LEDGF/p75
protein were used. Co-immunoprecipitation was performed in cells transiently cotransfected with plasmids encoding Flag-MeCP2 and one of the following eGFP-tagged
constructs: LEDGF/p75 (aa 1-530), LEDGF/p52 (aa 1-333), PWWP domain (aa 1-93),
ΔPWWP (aa 94-530), Δ1-325 (aa 325-530) or IBD (aa 347-429) (Fig 8A). Reciprocal
Co-IP showed that Flag-MeCP2 co-precipitated with both full length LEDGF/p75 and
p52 but not with any of the truncated LEDGF/p75 constructs (Fig 8B,C).
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Figure 7. LEDGF/p52 interacts with MeCP2. A) Schematic domain structure of
LEDGF/p75 and p52. B) Pull down assay was performed as described in the legend of
Figure 5A using recombinant His-LEDGF/p52. Protein input was determined by
immunoblotting of whole cell extracts.
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C

Figure 7. (C) LEDGF/p52 partially co-localizes with MeCP2 in the cell nucleus. Colocalization assay was performed as described in the legend of Figure 6C.
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Since both LEDGF/p75 and p52 interacted with MeCP2, and the PWWP domain
alone or ΔPWWP did not interact with MeCP2, we concluded that additional regions in
the N-terminal portion of these proteins may be needed for MeCP2 binding. To identify
these regions, deletion constructs consisting of the PWWP domain alone (aa 1-93), or in
combination with its downstream CR1 region (aa 1-141), were used to examine MeCP2
binding. U2OS cell lysates containing endogenous MeCP2 were incubated with the
following Flag-tagged recombinant proteins: LEDGF/p75, PWWP-CR1 (aa 1-141), or
PWWP (aa 1-108) (Fig 8A). Pull-down was done using anti-Flag agarose beads.
Immunoblotting analysis with anti-Flag antibody or anti-MeCP2 antibody showed that
endogenous MeCP2 was pulled down with Flag-LEDGF/p75 and Flag-PWWP-CR1 but
not with Flag-PWWP (Fig. 8D). This suggested that the extreme N-terminal region (aa
1-141) of LEDGF/p75 mediates its interaction with MeCP2.
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Figure 8. The N-terminus of LEDGF/p75 interacts with MeCP2. A) Diagram of
LEDGF/p75 deletion constructs used to map interaction regions.
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B

Figure 8. The N-terminus of LEDGF/p75 interacts with MeCP2. B) Flag-MeCP2 binds to
eGFP-LEDGF/p75 but not to eGFP-tagged truncated LEDGF/p75 constructs. 293T cells
ectopically overexpressing the tagged proteins labeled in the blot were
immunoprecipitated with GFP antibody and visualized by immunoblotting with
antibodies to GFP and Flag.
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Figure 8. The N-terminus of LEDGF interacts with MeCP2. C) Flag-MeCP2 binds to
eGFP-tagged LEDGF/p75 and LEDGF/p52 but not to truncated constructs. Proteins
ectopically overexpressed in U2OS cells were immunoprecipitated with Flag antibody
and visualized with both anti-GFP and anti-Flag antibodies. *Denotes degradation
product of LEDGF/p75. D) Recombinant Flag-LEDGF/p75, Flag-PWWP-CR1 (aa 1141) and Flag-PWWP (aa 1-101) were incubated with U2OS cell lysate. Proteins pulled
down with anti-Flag affinity matrix were detected by immunoblotting. Endogenous
MeCP2 in the cell lysate was pulled down by Flag-LEDGF/p75 and Flag-PWWP-CR1.
Flag-Adiponectin and absence of recombinant proteins (U2OS only) served as controls.
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MeCP2 Transactivates the Hsp27 Promoter
The interaction of LEDGF/p75 and p52 with MeCP2 suggested that these proteins
are part of a transcription complex that activates and regulates stress genes such as
HSP27. To examine this, we first determined if MeCP2 transactivates the Hsp27
promoter (Hsp27pr) in luciferase reporter assays. U2OS cells were transiently cotransfected with pGL3-Hsp27pr-Luc and either pcDNA-Flag-MeCP2, pCruz-HALEDGF/p75, or pCruz-HA-p52. Interestingly, transient overexpression of MeCP2
transactivated Hsp27pr at levels much higher (14 fold) (Fig 9A) than those induced by
LEDGF/p75 and p52 (2-3 fold) (Fig 9B). All three proteins transactivated Hsp27pr in a
dose dependent manner.
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Figure 9. LEDGF/p75, LEDGF/p52, and MeCP2 transactivate Hsp27 promoter. A)
U2OS cells were co-transfected with pGL3-Hsp27pr and increasing amount of pcDNAflag-MeCP2. Promoter activity determined as luciferase light units/protein is expressed as
fold activation compared to control activity (co-transfection of empty expression
vectors). Data from each graph is representative of one experiment, each of which was
repeated three or more times. Western blots show protein expression.
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Figure 9. LEDGF/p75, LEDGF/p52, and MeCP2 transactivate Hsp27 promoter. B)
U2OS cells were co-transfected with pGL3-Hsp27pr and increasing amount of pCruzHA
LEDGF/p75 or pCruzHA p52. Promoter activity determined as luciferase light
units/protein is expressed as fold activation compared to control activity (co-transfection
of empty expression vectors). Data from each graph is representative of one experiment,
each of which was repeated three or more times. Western blots show protein expression.
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To establish if transactivation of Hsp27pr by LEDGF/p75 and MeCP2 was
mediated by their binding to this promoter, chromatin immunoprecipitation (ChIP) assay
was performed. Based on previous reports, LEDGF/p75 was predicted to bind HSE and
STRE located in the proximal region (-185 to -111) of Hsp27pr (14), whereas MeCP2
was predicted to bind AT-rich repeats in the distal region (Fig. 9C) (38). ChIP assays
using a specific MeCP2 antibody revealed binding of this protein to Hsp27pr regions C
and D (bp -1071 to -382), located upstream of the HSE and STRE consensus sequences
(region A, Fig. 9D). On the other hand, LEDGF/p75 bound to the entire Hsp27pr tested
(bp -1071 to +18). ChIP with control rabbit anti-IgG did not produce any bands, while actin primers showed optimal enzymatic digestion of the chromatin. These results
indicated that both LEDGF/p75 and MeCp2 bind to the Hsp27pr, with overlapping
binding sites at the distal regions of the promoter.
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Figure 9. LEDGF/p75, LEDGF/p52, and MeCP2 transactivate Hsp27 promoter. C)
Schematic diagram of Hsp27pr showing AT rich regions, and HSE and STRE sites. PCR
primers targeted Hsp27pr regions A (bp -271 to +18), B (bp -480 to -220), C (bp -803 to 382), and D (bp -1071 to -781).
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Figure 9. LEDGF/p75, LEDGF/p52, and MeCP2 transactivate Hsp27 promoter. D)
Chromatin immunoprecipitation analysis of MeCP2 and LEDGF/p75 binding to Hsp27pr.
Formaldehyde fixed chromatin from U2OS cells was precipitated with non-specific IgG,
or antibodies specific for MeCP2 or LEDGF/p75.
PCR amplifications of
immunoprecipitated DNA derived from U2OS cells were carried out with primer sets
specific for Hsp27pr regions A to D. Hsp27pr primers amplified DNA fragments
precipitated by LEDGF/p75 antibody or MeCP2 antibody but not by IgG. Primers that
target human β-actin controlled for optimal enzymatic digestion of chromatin. Results are
representative of three experiments.
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LEDGF/p75 and p52 Modulate the Transcriptional Activity of MeCP2
Given that LEDGF/p75 and p52 bind MeCP2, and all three proteins transactivate
Hsp27pr in luciferase assays individually, with MeCP2 being the strongest activator
(Fig. 9A,B), we sought to determine if LEDGF/p75 and p52 influence the ability of
MeCP2 to transactivate Hsp27pr. Luciferase reporter assays were performed with coexpression of MeCP2 and LEDGF/p75, or MeCP2 and p52. Co-expression of induced
LEDGF/p75 and MeCP2 in U2OS cells significantly enhanced, although only moderately
and at low LEDGFp75/MeCP2 ratios, Hsp27pr transactivation levels above those by
MeCP2 alone (Fig 10A). However, co-expression of MeCP2 with p52, resulted in
significantly reduced Hsp27pr activity (Fig. 10B), suggesting that p52 represses MeCP2
transcriptional activity.
Since co-expression of LEDGF/p75 and MeCP2 did not result in robust increase
on Hsp27pr activity in U2OS cells, we transiently silenced endogenous LEDGF/p75
using small inhibitory RNAs (siRNAs) oligonucleotides, while transiently overexpressing
MeCP2, to further examine the functional relevance of the LEDGF/p75-MeCP2
interaction. Interestingly, U2OS cells with LEDGF/p75 knockdown and MeCP2
overexpression showed a dramatic and significant increase in Hsp27pr activation over
cells transfected with control siRNAs, suggesting that LEDGF/p75 regulates MeCP2driven Hsp27pr activity in these cells (Fig. 10C).
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Figure 10. LEDGF/p75 and p52 influence MeCP2-induced transactivation of Hsp27pr.
A) U2OS cells were co-transfected with 1.65g of pCruzHA or pCruzHA p75, and
increasing amount of pcDNA-flag-MeCP2 and pGL3-Hsp27pr-luc. Western blots show
protein expression. Data from graph is an average of five experiments. * indicates
significantly different from control (p<0.05). Western blots show protein expression.
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Figure 10. LEDGF/p75 and p52 influence MeCP2-induced transactivation of Hsp27pr. B)
U2OS cells were co-transfected with 1.65g of pCruzHA or pCruzHA p52, and increasing
amount of pcDNA-flag-MeCP2 and pGL3-Hsp27pr-luc. Western blots show protein
expression. Data from graph is an average of five experiments. * indicates significantly
different from control (p<0.05). Western blots show protein expression.
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Figure 10. LEDGF/p75 and p52 influence MeCP2-induced transactivation of Hsp27pr.
C) Transient knockdown of LEDGF/p75 results in increase of Hsp27pr activity in U2OS
cells, which is amplified by overexpression of MeCP2. Luciferase reporter assay shows
elevated Hsp27pr activity in the presence of MeCP2 when siRNA against LEDGF/p75
were employed. B) Western blots show protein expression.
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Given that both LEDGF/p75 and MeCP2 have been implicated in prostate cancer
cell growth and survival (33,34), we also examined the effects of their co-expression on
Hsp27pr in PC3 cells. First, we evaluated Hsp27pr activation in PC3 cells stably
overexpressing LEDGF/p75, and observed activation levels that were 3-5 fold above cells
stably transfected with empty pcDNA vector (Fig. 10D,E). Transient MeCP2
overexpression in PC3 cells stably transfected with empty vector did not significantly
increase Hsp27pr activation compared to cells without MeCP2 transfection (Fig. 10E),
which could be due to the low transfection efficiency of these cells. However, PC3 cells
overexpressing both LEDGF/p75 (stably) and MeCP2 (transiently) significantly
enhanced Hsp27pr activation compared to cells without MeCP2 transfection (Fig. 10E).
As observed with U2OS cells, PC3 cells with transient LEDGF/p75 knockdown and
transient MeCP2 overexpression showed a significant increase in Hsp27pr activation over
cells with normal LEDGF/p75 levels (Fig. 10F). Taken together, these results suggested
that LEDGF/p75 and p52 influence differently MeCP2-driven Hsp27pr activity in human
cancer cells.
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Figure 10. LEDGF/p75 and p52 influence MeCP2-induced transactivation of Hsp27pr.
A) PC3 cells stably transfected with empty pcDNA vector or pcDNA-LEDGF/p75 were
co-transfected with pGL3-Hsp27pr-luc and pMAX-GFP (transfection control). Promoter
activity determined as luciferase light units/GFP is expressed as fold activation compared
to control activity. Data represent the average of three or more experiments.
Immunoblots show protein expression. *p<0.05
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Figure 10. LEDGF/p75 and p52 influence MeCP2-induced transactivation of Hsp27pr..
B) PC3 cells stably transfected with empty pcDNA vector or pcDNA-LEDGF/p75 were
co-transfected with pGL3-Hsp27pr-luc and pcDNA-Flag-MeCP2. Promoter activity
determined as luciferase light units/GFP is expressed as fold activation compared to
control activity. Data represent the average of three or more experiments. Immunoblots
show protein expression. *p<0.05
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Figure 10. LEDGF/p75 and p52 influence MeCP2-induced transactivation of Hsp27pr.
C) PC3 cells stably transfected with empty pcDNA vector or pcDNA-LEDGF/p75 were
transfected with siRNA oligos to knockdown this protein. Cells were then co-transfected
with pGL3-Hsp27pr-luc and pcDNA-Flag-MeCP2. Promoter activity determined as
luciferase light units/GFP is expressed as fold activation compared to control activity.
Data represent the average of three or more experiments. Immunoblots show protein
expression. ** p<0.01.
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Discussion
In this study we established MeCP2 as a cellular interacting partner of
LEDGF/p75 using various complementary approaches. MeCP2 is a transcription factor
that was initially reported to bind methylated CpG islands and repress transcription
(35,39). More recently, it has been reported that MeCP2 binds DNA regardless of
methylation status and does not necessarily function in transcriptional repression, since it
can activate transcription in association with specific factors (36,40,41). We
demonstrated that MeCP2 binds to the extreme N-terminal region of LEDGF/p75, which
implies that it does not compete with HIV1-IN for LEDGF/p75 binding. Our results
suggested that the PWWP domain of LEDGF/p75 alone is not sufficient to bind MeCP2
and that the downstream CR1 domain is also required. The CR2/SRD domain, also
present in LEDGF/p52, may stabilize the interaction with MeCP2 by providing additional
binding points.
To the best of our knowledge, these results represent the first direct demonstration
that the PWWP-CR1 domain of LEDGF/p75 is involved in protein-protein interactions.
This region was initially thought to bind directly to DNA, but was later shown to be
insufficient for DNA binding (32). Instead, the NLS and AT-hooks are the main motifs
involved in DNA binding, leaving the PWWP domain free to interact with chromatin
proteins (25,26). The PWWP domain is conserved in some DNA binding proteins, and
appears to be targeted to specific regions of chromatin for interaction, not necessarily
with DNA, but with different chromatin proteins (42,43).
We examined whether the LEDGF/p75-MeCP2 interaction influences the
transactivation of Hsp27pr in luciferase reporter assays. Hsp27 is known to be a target
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gene of LEDGF/p75 and has been implicated in prostate cancer resistance to cell death
and chemotherapy (14,21,44,45). We have previously shown that overexpression of
LEDGF/p75 or p52 upregulates Hsp27 transcript, correlating with its promoter
transactivation (21). Our results revealed that MeCP2 overexpression robustly
transactivated Hsp27pr in U2OS cells, surpassing the levels of transactivation induced by
LEDGF/p75 or p52. However, we did not observe a robust synergistic effect between
MeCP2 and LEDGF/p75 on Hsp27pr activation in U2OS cells. This could be due to
high endogenous levels of LEDGF/p75 in this cell line, which may have reached
saturation levels. We cannot exclude the possibility that the lack of further activation by
the interaction between these two proteins is due to limitations of the assay. However,
co-expression of both proteins in PC3 prostate cancer cells resulted in significantly
enhanced promoter transactivation when compared to individual protein expression.
These results suggest that the LEDGF/p75-MeCP2 interaction enhances Hsp27pr
activation depending on the intracellular levels of these proteins or the cellular context.
Co-expression of LEDGF/p52 with MeCP2 in U2OS cells resulted in reduced
transactivation of Hsp27pr, suggesting that p52 represses the transcriptional activity of
MeCP2. Bueno et al. (20) recently reported that mutations impairing SUMOylation of
LEDGF/p75 increase its transcriptional activity, but not that of p52, suggesting that these
splice variants may activate Hsp27pr via different molecular mechanisms. Considering
the antagonistic functions of LEDGF/p75 (pro-survival) and p52 (pro-apoptotic) (21), it
is possible that the latter may compete with LEDGF/p75 in binding to MeCP2 and
Hsp27pr, thus preventing their interaction with the general transcription complex. In
addition, p52, which lacks the C-terminal domain of LEDGF/p75 implicated in pro-
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survival functions (1,5,21,32), may be unable to promote cellular survival because of its
inability to interact with survival proteins. It is possible that interaction of the C-terminal
region of LEDGF/p75 with other proteins, such as the Myc-interacting protein JPO2 (30),
is important to fine tune transcription regulation of stress and survival genes. The
binding of p52 to MeCP2 could also form a growth suppressor unit, down-regulating the
activation of Hsp27pr, similar to that of the growth suppressor unit formed by interaction
of JunD with menin (46). Alternatively, reduced Hsp27pr activity may be due to p52induced apoptosis, which leads to inactivation of transcription signals.
Our observations that transient LEDGF/p75 silencing in both U2OS and PC3 cells
induced a dramatic increase in MeCP2-driven Hsp27pr activity, suggested that MeCP2 is
a main modulator of this promoter, with LEDGF/p75 playing a regulatory role. It is
possible that LEDGF/p75 could tether MeCP2 to the chromatin, as it does with HIV-IN
and the menin/MLL complex (6,17), and regulate its transcriptional activity through
interaction with other transcription factors or co-activators. Since siRNA-mediated
silencing is not 100% efficient, low endogenous levels of LEDGF/p75 could still be
sufficient for MeCP2 binding to the promoter region. Alternatively, LEDGF/p75 may be
part of a feedback loop by competing with MeCP2 or blocking other transcription cofactors from promoter regulatory sites in the presence of high MeCP2 levels, as in the
feedback loop observed between HSF1 and Hsp27 (47).
Consistent with our promoter reporter assays, we demonstrated the binding of
LEDGF/p75 and MeCP2 to Hsp27pr by ChIP assays. Interestingly, binding of
LEDGF/p75 was not limited to the region where HSE and STRE are located (bp -271 to
+18), but also to the entire Hsp27pr region tested (bp -1071 to -220). This observation
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sheds some light into the question of whether LEDGF/p75 binding to promoter regions is
mainly restricted to STRE and HSE as reported by Singh’s group (14,32), but not
observed by Engelman’s group (26). Recently, members of this research team used the
DamID technology, focusing on the highly annotated ENCODE (encyclopedia of DNA
Elements) region, to demonstrate that LEDGF/p75 binding to DNA occurs primarily
downstream of active transcription unit start sites (48). LEDGF/p75 binding was not
restricted to STREs, but correlated with active chromatin markers and RNA polymerase
II binding (18). However, STREs appear to be important for LEDGF/p75 mediated
VEGF-c promoter transactivation (16). It is plausible that LEDGF/p75 binding to
particular promoter regions might be influenced by interactions with specific proteins,
and the cellular type and microenvironment.
Binding of MeCP2 to Hsp27pr was observed upstream of HSE and STRE sites in
AT-rich regions (bp-1071 to -382) as predicted (38), sharing this region with
LEDGF/p75. Prior to this study, there have been no reports documenting MeCP2
binding to and activation of Hsp27pr. In agreement with our results, MeCP2 has been
shown to directly bind promoter sites of proteins and enhance their function, as
demonstrated by its association with Creb1 on promoters of transcribed genes (36). It is
possible that MeCP2 interacts with other transcription factors on Hsp27pr in a manner
similar to its association with Creb1 at promoter sites, contributing to up-regulation of
Hsp27pr activity in human cancer cells.
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Conclusion
In conclusion, we validated MeCP2 as a specific cellular interacting partner of
both LEDGF/p75 and p52, and a novel transactivator of Hsp27pr. Since MeCP2
represses or enhances gene activation in association with other transcription factors, it is
possible that its binding to LEDGF/p75 and p52 may result in targeting specific
promoters to either protect cells from stress-induced cell death or trigger cell death (49).
Although additional work is required to fully establish the role of LEDGF/p75, p52, and
MeCP2 in stress gene regulation in tumor cells, our results lay the groundwork for future
studies focused on modulating the transcriptional functions of these proteins to
circumvent tumor resistance to cell death and chemotherapy.
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CHAPTER THREE
RESULTS IN PROGRESS NOT INCLUDED IN PUBLICATIONS

Introduction
LEDGF/p75 is a known survival protein that has been linked to attenuation of cell
death induced by DTX and oxidative stress [1, 2]. This protection might be related to the
protein’s ability to upregulate stress related proteins. Its interaction with MeCP2 shows
transactivation of Hsp27pr activity (Chapter 2). Other stress response proteins such as
oxidoreductase ERp57 has been implicated in attenuation of cell death induced by
oxidative stress in various systems [3]. Insulin-like growth factors binding protein 5
(IGFBP-5) is the major IGFBP that binds IGF, the most abundant growth factors in the
bone matrix. PSA derived from PCa cells was reported to enhance IGF bioavailability in
the bone microenvironment of PCa metastasis, thereby permitting PCa survival and
malignant progression in the bone microenvironment [4]. To examine if LEDGF-MeCP2
complex modulates other stress response proteins in PCa, we examined their function on
ERp57pr and IGFBP5pr. The transactivation functions of cleaved constructs of
LEDGF/p75 were also examined. In addition, we examined if LEDGF/p75 selectively
protects against stress-induced non-apoptotic cell death. The results presented in this
chapter were obtained from preliminary experiments relevant to Chapter two and other
publications currently in preparation. Some of these results are likely to lead to new ideas
for research projects.
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Materials and Methods
Induction of Cell Death
Cell death was induced by treatment with TBHP (150 μM), TRAIL/actinomycin
D (100 ng/ml each), or 4 μM STS for up to 24 h. Cells morphology was visualized on an
Olympus IX70 microscope equipped with Hoffmann Modulation Contrast (Olympus
American). Images were acquired using a digital Spot Imaging System (Diagnostic
Instruments).

Cell Viability Assays
Cells seeded in 96-well plates (3 x 104 cells per well) were treated with cytotoxic
drugs, washed with phosphate buffered saline (PBS), and fixed in 4% paraformaldehyde
for 1 h at 4°C. Cells were then washed three times with distilled water, and Accustain
Crystal Violet solution (Sigma-Aldrich) (1:4) was added to each well followed by
incubation for 20 minutes at room temperature. Plates were washed with distilled water to
remove excess dye and then dried at room temperature. Acetic acid (10% v/v) was added
to each well for 10 minutes and absorbance was measured at 570 nanometers (nm) using
a μQuant microplate reader (Bio-tek Instruments).

Measurement of ROS by Flow Cytometric Analysis
Generation of reactive oxygen species (ROS) were assessed based on the
intracellular oxidation of 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA,
Invitrogen) to form the fluorescent compound 2’,7’-dicholorofluorescein (DCF). Cells
were seeded in a 6-well plate at a density of 3 x 105 cells per well and cultured for 24
hours. Treatment of cells with the drugs was done for up to 12 h. Then, DCFH-DA (0.5
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μM) was added to the cells, followed by incubation for 20 minutes at 37°C. The cells
were washed with PBS (2X), and then resuspended in 0.5 mL of PBS. Fluorescence
intensity was determined by flow cytometry using the FACScalibur (BD Biosciences).

Results
Additional Studies on the LEDGF-MeCP2 Interaction
Binding of LEDGF PWWP CR1 to MeCP2
U2OS cell lysates containing endogenous MeCP2 were incubated with
recombinant Flag-LEDGF/p75, Flag-PWWP CR1 (res 1-141) or Flag-PWWP (res 1108). This mixture was pulled down with anti-Flag agarose. Immunoblotting using
antibody against MeCP2 showed MeCP2 being pulled down with Flag-p75 and FlagPWWP CR1 but not with Flag-PWWP. This suggests that the extreme N-terminal (108
res) part of LEDGF mediates interaction with MeCP2 (Chapter 2 Fig 8). To further
characterize these interactions, we conducted AlphaScreen® assays. Due to high
degradation of MeCP2 and difficulties in using purified GST MeCP2 in AlphaScreen®
assays, we opted to use GST MeCP2 present in bacterial lysate. Induction of GST
MeCP2 was increased by the addition of sorbitol and betaine, which creates osmotic
stress for intake of stabilizing biomolecules. The solutes also assist in protein folding in a
chaperone-like manner. AlphaScreen® counts showed binding of purified flag-PWWP
CR1 to GST MeCP2 in bacterial lysate, although in relatively lower binding capacity
compared to full length LEDGF/p75 binding to MeCP2 (Fig 11A,B). Non-transformed
bacterial lysate served as negative control (Fig 11C).
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A

Figure 11. The N-terminus of LEDGF interacts with MeCP2. PWWP CR1 binds MeCP2
as confirmed by AlphaScreen® assay. Purified flag PWWP CR1 was incubated with
GST-MeCP2 in bacterial lysate for 1 h. Glutathione donor beads and flag acceptor beads
were then added, and plates were read on an EnVision multilabel plate reader after 2 h
incubation period in the absence of light. A) Cross titration for Flag-LEDGF-PWWPCR1 and GST-MeCP2 shows interaction as measured by AlphaScreen® assays.
Interaction was measured at different concentrations of Flag-LEDGF-PWWP-CR1 as
indicated in the legend and GST-MeCP2 as indicated on the X-axis.
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Figure 11. The N-terminus of LEDGF interacts with MeCP2. B) 50nM of PWWP CR1 is
required to bind MeCP2. C) Non-transformed bacterial lysate control does not bind to
MeCP2.
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Co-localization assays were also performed to confirm protein interactions. U2OS
cells were transfected with pEGFP-PWWP or pEGFP-∆PWWP with pcDNA-flagMeCP2. Rhodamine dye was used to detect MeCP2 localization. Confocal fluorescence
microscopy was used to visualize proteins, showing partial co-localization of both
LEDGF constructs with MeCP2 (Fig11D,E).
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D

E

Figure 11. The N-terminus of LEDGF interacts with MeCP2. Localization of PWWP and
MeCP2 in the nucleus. U2OS cells plated on chamber slides were transfected with
pcDNA-Flag-MeCP2 and D) peGFP-PWWP or E) peGFP-∆PWWP using Trans-It®
2020 (Mirus). Ectopically expressed LEDGF or MeCP2 were detected using specific
antibodies, followed by specific anti-rhodamine antibody. The nuclei were subsequently
stained with DAPI and fluorescent signals were analyzed by confocal fluorescence
microscopy 48h post-transfection.
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Transactivation of Hsp27pr by LEDGF/p75 and MeCP2 in PC3 Cells
To examine if Hsp27pr transactivation also occurs in PCa cells, PC3 cells with
stable overexpression or knockdown of LEDGF/p75 were generated. The cells were
transiently transfected with 0.4ug pGL3-Hsp27pr. Luciferase activity shows correlation
of Hsp27pr with LEDGF/p75 expression (Fig 12A). To examine if MeCP2 interaction
influences transactivation of Hsp27pr, MeCP2 was transiently transfected in PC3 cells
overexpressing LEDGF/p75. Ectopic expression of MeCP2 in PC3 cells stably
overexpressing LEDGF/p75 increased transactivation of Hsp27pr threefold (Fig 12B).
PC3 cells were co-transfected with 0.4ug pGL3-Hsp27pr, pcDNA or pcDNA-flagMeCP2.

Transactivation of ERp57pr by LEDGF/p75 and MeCP2
In light of the documented role of LEDGF/p75 as a transcription co-activator that
promotes protection of mammalian cells from stress-induced cell death through the
transcriptional upregulation of stress response proteins, we performed stress protein
profiling via Kinetworks™ to identify proteins that could be upregulated by LEDGF/p75
overexpression [5]. ERp57 showed a 33.55 fold increase in protein expression in whole
cell lysates from RWPE-2 cells stably overexpressing LEDGF/p75 compared to cells
stably transfected with empty pcDNA vector [5]. Since LEDGF/p75 was shown to
transactivate the ERp57 promoter, we subsequently determined the correlation of protein
expression in PCa cell lines and tissue. In the panel of prostate cell lines (PrEC, PrSC and
RWPE-1), BHP (55T), and PCa cell lines (RWPE-2, PC3, DU145, LnCaP, 22RV1, MDA
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Figure 12. MeCP2 up-regulates Hsp27pr activity in PCa cells. A) Hsp27pr activity of
PC3 cells with stable overexpression and knockdown of LEDGF/p75 was analyzed using
luciferase reporter assay. B) pcDNA MeCP2 was overexpressed in PC3 cells stably
overexpressing LEDGF/p75. Increased Hsp27pr activity was observed in the presence of
LEDGF/p75 and MeCP2.
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and 41T) examined, no evident correlation between the expression of both LEDGF/p75
and ERp57 was found [6]. Contrary to this, immunohistochemical analysis of prostate
tissue microarrays (TMA) showed correlation of LEDGF/p75 and ERp57 expression at
the tissue level (p value < 0.0001, Kendall’s tau b analysis) (Basu,A et al., unpublished
results). However, the expression of ERp57 in two PCa cell lines (PC3 and RWPE-2)
with LEDGF/p75 transient siRNA-mediated knockdown showed no downregulation of
ERp57 when LEDGF/p75 was knocked down (manuscript in preparation). Nevertheless,
we cannot rule out the fact that minimal levels of LEDGF/p75 are sufficient to stimulate
ERp57 expression, since total repression of HIV1 replication was only achieved when
LEDGF/p75 knockdown was over 97%.
To examine if LEDGF/p75-MeCP2 similarly transactivates ERp57pr in other cell
types, luciferase reporter assays were performed. U2OS cells were transiently cotransfected with pcDNA-Flag-MeCP2, pCruzHA-LEDGF/p75 or pCruzHA-p52 or
pCruzHA-p38 and a promoter construct containing -262 to -22 bp of the human ERp527
gene in pGL3 luciferase reporter. MeCP2 overexpression up-regulated ERp57pr activity
seven fold (Fig 13B), compared to two fold of LEDGF/p75 (Fig 13A). p52 and p38
transactivated ERp57pr to a lesser degree. Co-expression of MeCP2 with all LEDGF
constructs showed further up-regulation of ERp57pr that corresponds to MeCP2
transactivation (Fig 13C).
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Figure 13. LEDGF/p75 and MeCP2 upregulate ERp57pr activity. A) Transient
transfection of pCruzHA-p75 or pCruzHA-p52 B) pcDNA-MeCP2, with pGL3Hsp27pr-Luc in U2OS resulted in significant increase of ERp57pr activity.
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Figure 13. LEDGF/p75 and MeCP2 upregulate ERp57pr activity. C) Co-expression of
the plasmids in U2OS. GFP was transfected as control for transfection efficiency.
Promoter activity determined as luciferase light units/gfp is expressed as fold activation
compared to control activity (co-transfection of empty expression vectors). Results are
average of three or more experiments.
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In PC3 cells, stable overexpression of LEDGF/p75 upregulated ERp57pr up to
three fold (Fig 13D). However, PC3 cells with stable knockdown of LEDGF/p75 showed
similar upregulation of ERp57pr. Overexpression of MeCP2 in PC3 cells stably
overexpressing LEDGF/p75 increased transactivation of ERp57pr another four fold (Fig
13E). Fold activation is relative luciferase units normalized against gfp for transfection
efficiency.

Transactivation of IGFBP5pr by LEDGF/p75 and MeCP2
To explore if LEDGF-MeCP2 interaction modulates transactivation of Hsp27pr
but not ERp57pr, we examined another protein implicated in PCa, IGFBP5pr. U2OS cells
were transiently co-transfected with pcDNA-flag-MeCP2, pCruzHA-LEDGF/p75 or
pCruzHA-p52 or pCruzHA-p38 and a promoter construct containing -252 to +24 bp of
the human IGFBP5pr gene in pGL3 luciferase reporter as described in Perez-Casellas et
al. MeCP2 overexpression up-regulated IGFBP5pr activity twelve fold (Fig 14B),
compared to six fold of LEDGF/p75 (Fig 14A). p52 and p38 transactivated IGFBP5pr to
a lesser degree. In PC3 cells, stable overexpression of LEDGF/p75 upregulated
IGFBP5pr three fold, while stable knockdown of LEDGF/p75 downregulated IGFBP5pr
to basal levels (Fig 14C).
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Figure 13. LEDGF/p75 and MeCP2 up-regulate ERp57pr activity. D) PC3 cells with
stable overexpression or knockdown of LEDGF/p75 were transfected with pGL3ERp57pr-luc. ERP57pr acitivity does not correlate with LEDGF/p75 expression. E)
MeCP2 was transiently overexpressed in PC3 cells stably overexpressing LEDGF/p75.
Co-expression of both proteins upregulated Hsp27pr threefold. GFP was transfected as
control for transfection efficiency. Promoter activity determined as luciferase light
units/gfp is expressed as fold activation compared to control activity (co-transfection of
empty expression vectors). Results are average of four or more experiments.
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Figure 14. LEDGF/p75 and MeCP2 up-regulate IGFBP5pr activity. A) Transient
transfection of pCruzHA-p75, pCruzHA-p52, or B) pcDNA-MeCP2with pGL3Hsp27pr-Luc in U2OS resulted in significant increase of Hsp27pr activity. Results are
representative of three experiments.
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Figure 14. LEDGF/p75 and MeCP2 up-regulate IGFBP5pr activity. C) PC3 cells with
stable overexpression or knockdown of LEDGF/p75 were transfected with pGL3IGFBP5pr-luc. GFP was transfected as control for transfection efficiency. Promoter
activity determined as luciferase light units/gfp is expressed as fold activation compared
to control activity (co-transfection of empty expression vectors). Results are average of
three experiments.
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Transactivation of Hsp27pr by LEDGF/p75 Cleaved Constructs
During apoptosis, LEDGF/p75 is cleaved by caspases into different fragments
(Fig 15A), which abolishes its pro-survival functions [7]. Cleavage of N-terminal
domain of LEDGF/p75 was shown to upregulate Hsp27pr transactivation [8], suggesting
a repressive function. To examine if MeCP2 modulates this transactivation, we
transiently overexpressed LEDGF/p75 cleaved constructs in the presence and absence of
MeCP2 with Hsp27pr. The removal of N-terminal 30aa results in an increase in Hsp27pr
transactivation (Fig 15B). However, further removal of C-terminal 44aa showed a slight
decrease in this activation, suggesting the involvement of this region in transactivation
(Fig 15B). Co-expression of MeCP2 further enhanced Hsp27pr activation up to three fold
(Fig 15C).

Regulation of LEDGF/p75 by MeCP2
While confirming protein expression of LEDGF/p75 and MeCP2 in luciferase
reporter assay, we observed that co-expression of MeCP2 and LEDGF/p75 shows
decreased levels of MeCP2. To further examine this, we co-expressed pCruzHA,
pCruzHA-p75, pCruzHA-p52 in the absence and presence of pcDNA-flag-MeCP2 in
U2OS cells. Co-expression of LEDGF/p75 and MeCP2 shows down-regulation of
MeCP2 protein levels (Fig 16).
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Figure 15. Transactivation of Hsp27pr by LEDGF/p75 constructs. During apoptosis,
LEDGF/p75 is cleaved by caspases-3 at its N-terminal and C-terminal region.
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Figure 15. Transactivation of Hsp27pr by LEDGF/p75 constructs. B) Transient
transfection of pCruzHA-p75, pCruzHA-p72, pCruzHA-68, or pCruzHA-p65 with pGL3Hsp27pr-Luc in U2OS in U2OS cells. Significant increase of Hsp27pr activity was
observed with p72 and p65 overexpression. Promoter activity determined as luciferase
light units/protein is expressed as fold activation compared to control activity (cotransfection of empty expression vectors). C) Co-expression of pcDNA-MeCP2 with
LEDGF/p75 constructs mentioned in A with pGL3-Hsp27pr-Luc in U2OS. Results are
representative of three experiments.
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Figure 16. Regulation of LEDGF/p75 by MeCP2. Western blot shows protein expression
levels of LEDGF/p75, p52 and MeCP2. Co-expression of LEDGF/p75 with Flag-MeCP2
(lane 5) shows decreased levels of MeCP2 compared to Flag-MeCP2 overexpression
alone (lane 4).
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Interaction of Menin with MeCP2
Menin/MLL was reported to interact with LEDGF/p75, which facilitates its
integration to chromatin and allows transcription and leukemic transformation [9]. To
examine if menin interacts with LEDGF/p75, pull down assays were performed using
GST-LEDGF/p75 with U2OS or PC3 cell lysate. Western blots show LEDGF/p75
binding to menin (Fig 17A, B). To examine if menin also interacts with MeCP2, U2OS
lysate was incubated with recombinant GST MeCP2. Pull down assays showed binding
of MeCP2 to menin (Fig 17C). This suggests that LEDGF/p75 may interact in a complex
with MeCP2 and menin.

Role of Overexpressed LEDGF/p75 in Protection Against Oxidative
Stress-induced Cell Death
LEDGF/p75 Overexpression Protects Cells from TBHP Treatment
We have shown that LEDGF/p75 protects cells from serum deprivation [7] and
DTX-induced cell death [1]. LEDGF/p75 also protects RWPE-2 (transformed prostate)
cells from TBHP-induced non-apoptotic cell death (unpublished data). To examine if this
protection occurs in PC3 cells, we generated PC3 cells stably overexpressing
LEDGF/p75. The cells were then treated with increasing doses of TBHP for 6, 12, and
24h. Cell survival was analyzed using crystal violet assay (Fig 18A). Pictures of cellular
and nuclear morphology show protection of LEDGF/p75 against TBHP treatment (Fig
18B). To understand how LEDGF/p75 protects against TBHP-induced cell death, we
examined ROS levels measured using DCFH-DA staining via flow cytometry.
LEDGF/p75 overexpression reduced ROS generated by TBHP, STS and TRAIL (Fig
18C).
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Figure 17. Interaction of Menin with LEDGF/p75. Pull down assays of GST-LEDGF/p75
and menin. GST-MeCP2 or GST beads were incubated with A) PC3 or B) U2OS lysates.
Samples brought down by glutathione beads were analyzed by western blot. Left panel
shows immunoblot of input proteins. Pull down Assays were performed by Leslimar
Rios-Colon, graduate student in our laboratory.
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Figure 17. Interaction of Menin with MeCP2 in U2OS cells. C) Pull down assays of
GST-MeCP2 and menin. GST-MeCP2 or GST beads were incubated with U2OS lysates.
Samples brought down by glutathione beads were analyzed by western blot. Left panel
shows immunoblot of input proteins.
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A

Figure 18. LEDGF/p75 overexpression protects against TBHP treatment. A) Percentage
of surviving PC3 cells treated with 50, 75 or 150 μM TBHP, 100 ng/mL TRAIL/Act.D or
4 μM STS. Cell viability was determined by crystal violet staining. Absorbance was
measured at 570 nm and the values were normalized against those of untreated cells,
which were assumed to be 100% viable. Errors bars represent the standard deviation of
at least three independent experiments done in triplicate. * p<0.05; **p< 0.01
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B

Figure 18. LEDGF/p75 overexpression protects against TBHP treatment. B) Cellular
morphology of PC3 cells treated with TBHP, TRAIL/Act.D and STS as in A) for 12 h.
Cell morphology visualized by Hoffman modulation microscopy.
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C

Figure 18. LEDGF/p75 overexpression protects against TBHP treatment. C) LEDGF/p75
overexpression reduces ROS levels. PC3 cells stably overexpressing LEDGF/p75 were
treated with 75, 100 μM TBHP, 100 ng/mL TRAIL/Act.D or 4 μM STS for 6 h. Cells
were incubated with DCFH-DA dye and analyzed via flow cytometry. Results show
reduction of ROS in the cells. Results are representative of three experiments. * p<0.5
compared to vector control.
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Discussion
The binding of MeCP2 to the N-terminal region of LEDGF/p75, PWWP CR1, is
likely a weak interaction which is probably strengthened by the additional region (CR2)
present in p52. Both PWWP and ∆PWWP constructs partially co-localize with MeCP2 in
the cell nucleus.
LEDGF/p75 and MeCP2 upregulate Hsp27pr in PC3 cells in a manner similar to
that observed in U2OS cells, suggesting that this interaction occur in PCa. Interestingly,
co-expression of LEDGF/p75 and MeCP2 led to synergistic transcriptional activity of
Hsp27pr in PC3 cells not observed in U2OS cells (Chapter two), suggesting a cell type
specific regulation. As an example of a precedent for this phenomenon, HoxA10
expression was reported to increase activity of IGFBP1pr in endometrial stromal and
glandular cells but not in decidual cells [10]. In addition, SOX proteins Likewise, ectopic
expression of MeCP2 also resulted in a higher increase of ERp57pr activation compared
to overexpression of LEDGF/p75. However, ERp57pr activity remained upregulated
when LEDGF/p75 levels were repressed, suggesting that MeCP2 could be the main
transactivator of ERp57pr. In this situation, it could bind a different response site that is
not blocked by LEDGF/p75. Further experiments should examine MeCP2’s role in
ERp57pr transactivation by repressing its expression. Similar to Hsp27pr and ERp57pr,
IGFBP5pr activity was highly upregulated by MeCP2. The knockdown of LEDGF/p75
was shown to downregulate IGFBP5pr activity. Future experiments should examine
modulation of IGFBP5pr in the presence of both LEDGF/p75 and MeCP2. Our results
suggest that LEDGF-MeCP2 interacts with various stress proteins in a different manner,
and that their transactivation function may involve other cofactors.
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Caspase-mediated cleavage of intracellular proteins occurs commonly in
apoptosis. Many transcription factors, regulators of cell growth, proliferation and
apoptosis are cleaved by caspase-3, converting them into functionally inactive fragments
or fragments exhibiting dominant-interfering functions that amplify the cell death process
[11]. For example, cleavage of Forkhead transcription factor FOXO3a results in
fragments with reduced transcriptional activity [12]. However, removal of LEDGF/p75
N-terminal 30aa increased transactivation of Hsp27pr, suggesting a repressive function of
this region. On the other hand, further removal of C-terminus region resulted in a slight
decrease in elevated transactivation, suggesting its involvement in transactivation. The
addition of MeCP2 greatly enhanced this transactivation, suggesting that it plays a major
role in upregulation of Hsp27pr. However, correlation between pro-survival function and
Hsp27pr transactivation remains unknown.
LEDGF/p75 overexpression protects PC3 cells from TBHP treatment but not
from the classical apoptosis inducers TRAIL and STS. However, this overexpression
reduced ROS levels generated by all three treatments. Additional experiments are needed
to examine if this effect is general or chemospecific. Further experiments should include
examining pathways upstream of ROS generation. Since LEDGF/p75 protects cells from
oxidative stress-induced cell death, further experiments should examine if overexpression
of MeCP2 contributes to this protection against TBHP and DTX, or if the protection is
conferred through LEDGF’s interaction with other proteins. The decreased expression of
MeCP2 in the presence of LEDGF/p75 suggests negative regulation or presence of a
feedback loop. We cannot rule out the possibility that protein expression was regulated
by the cells to avoid toxicity as a result of protein saturation. The interaction of menin
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with MeCP2 suggests its possible involvement in transactivation of stress proteins.
Examining the menin-LEDGF-MeCP2 complex will lead to deeper understanding of the
interactome that controls transcription and allow for multiple target points in therapy.
Regulation of transcription involves multiple players and variations in different
contexts. These studies show that the interaction between LEDGF and MeCP2 and their
modulation of stress protein transactivation requires further investigation.
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CHAPTER FOUR
OVERALL DISCUSSION

Interaction of LEDGF/p75 and MeCP2
LEDGF/p75 shares the following similarities with high mobility group (HMG)
family members: abundant charged and proline residues; presence of AT-hook motifs;
and little secondary structure [1]. Based on these similarities, it is speculated that they
might share similar functions, namely in multiple interactions with proteins and
DNA/chromatin. In Sry-related HMG box (SOX) proteins, the HMG domain doubles as
both the DNA-binding moiety and the major interface for protein–protein interaction, in
agreement with previous reports that HMG domain interacts with other transcriptional
co-regulators and in nuclear import [2]. Further examinations revealed that the NLS and
AT-hooks are the main players in LEDGF/p75 chromatin binding, with PWWP playing a
supporting role [3] and available for protein-protein interactions.
LEDGF/p75 gene expression is upregulated in PCa cell lines and tissue [4] . Its
protein expression is upregulated in response to heat and oxidative stress, and promotes
resistance of mammalian cells to stress induced cell death [5-9]. In addition,
overexpression of LEDGF/p75 conferred a protective effect against DTX- and TBHPinduced cell death [10] (Chapter Three). It is presumed that the stress survival functions
of LEDGF/p75 are associated with its ability to transcriptionally activate stress genes via
interaction with heat shock elements (HSE) and stress response elements (STRE) in
promoter regions of stress proteins such as antioxidant protein 2 (AOP2/Prdx6),
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involucrin, alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), Hsp27, and
B-crystallin [8, 11-14]. Since the mechanisms by which it confers resistance to
oxidative stress and chemotherapeutic agents are not well understood, we examined its
interaction with other transcription factors.
MeCP2 was initially discovered to bind methylated CpG islands and repress
transcription [15]. It also protects mice from N-methyl-d-aspartate (NMDA) and αamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA)-induced
excitotoxicity and hypoxic-ischemic insult, possibly through repressing caspase-3
activation [16]. Binding of LEDGF/p75 to MeCP2 might be part of a transcription
complex that serves to protect cells from stress-induced cell death by regulating the
expression of stress protective genes. LEDGF/p75 was shown to bind MeCP2 through its
N-terminal regions (Chapter two). This interaction was mapped to PWWP CR1, and
retained the protein’s chromatin association. The interaction between LEDGF/p52 and
MeCP2 was stronger compared to that with PWWP CR1, possibly due to the additional
CR2 region present in LEDGF/p52, which may stabilize interaction with MeCP2 by
having additional interaction points. Given the lack of secondary structure of both
LEDGF/p75 and MeCP2, the binding of LEDGF/p75 to MeCP2 may cause
conformational changes that allow it to bind transcription sites, thus modulating their
functions and interactions with other proteins.

Functional Implications of LEDGF/p75 and MeCP2 Interaction
As mentioned previously, LEDGF/p75 is a survival protein and transcriptional coactivator upregulated in PCa cell lines and tissues [4]. Early studies on LEDGF/p75
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uncovered its pro-survival properties in lens epithelial cells (LECs) [14], where
overexpression of LEDGF/p75 was shown to protect against thermal and oxidative stress
[14]. LEDGF/p75 overexpressing cells showed upregulation of Hsp27 and B-crystallin
[14], enhanced growth rate [17], and prolonged cell survival in the absence of serum [17].
Since LEDGF interacts with MeCP2, we examined the functional impact of this
interaction on transcriptional activity.

Transactivation Functions of LEDGF-MeCP2
Binding of MeCP2 to LEDGF/p75 could lead to recruitment of transcription
activator proteins such as CREB1, which subsequently activates genes that confer
resistance to oxidative stress-induced cell death in PCa cells. In light of our data, which
shows MeCP2 as the main transactivator of Hsp27pr (Chapter Two), we examined if this
effect is also observed with thiol-disulfide oxidoreductase ERp57pr and tumor suppressor
IGFBP5pr. Our results (Chapter Three) suggested that MeCP2 is a main transactivator of
these proteins, compared to LEDGF/p75. Overexpression of MeCP2 greatly
transactivates Hsp27pr, surpassing the level of transactivation induced by LEDGF/p75 or
p52 up to three fold. Knockdown of endogenous LEDGF/p75 expression further
increased Hsp27 promoter activity (up to four fold) in the presence of ectopic MeCP2 in
U2OS cells, compared to siRNA control knockdown cells, suggesting that MeCP2 is a
strong modulator of Hsp27pr activity. LEDGF/p75 seems to repress transactivation of
Hsp27pr activity by MeCP2 in U2OS, suggesting that it plays a regulatory role. It is not
clear if this phenomenon is promoter and cell type specific.
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Generally, transcription coactivators interact with DNA–binding transcription
factors to confer synergistic activation of gene expression [18]. This seems to occur with
Hsp27pr and ERp57pr in PC3 cells overexpressing both LEDGF/p75 and MeCP2
(Chapter Three). In this context, MeCP2 may associate with CREB1 to facilitate
transcription. On the other hand, LEDGF/p75 may interfere with MeCP2 transactivation
in U2OS cells by blocking it from binding to Hsp27pr, or by blocking its activation site.
Alternatively, up-regulation of Hsp27pr might be dependent on a different combination
or order of assembly of co-factors to its promoter site, as in the case of MTF-1 activator
[19]. Furthermore, it is possible that LEDGF/p75-mediated repression of MeCP2 activity
could be modulated by another transcription factor. We cannot exclude the possibility
that LEDGF/p75-MeCP2 may exist in a feedback loop, with high levels of MeCP2
stimulating repression by LEDGF/p75, as seen in the feedback loop observed between
heat shock transcriptional factor 1 (HSF1) and heat shock proteins [20, 21]. LEDGF may
regulate persistent, increased activity of MeCP2 to avoid induction of cell death as in the
case of Stress-activated protein kinase (SAPK) [22]. Further experiments should examine
MeCP2 transactivation function in the presence and absence of LEDGF/p75 and other cofactors.

Novel Binding of LEDGF/p75 and MeCP2 to Hsp27pr
LEDGF/p75 has been shown to bind stress response elements and heat shock
elements in Hsp27 promoter region in electrophoretic mobility shift assay (EMSA)
assays using both purified protein and HeLa nuclear extracts [23]. However, this binding
could not be confirmed by other investigators who suggested it was non-specific
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[3](unpublished data). A recent report showed LEDGF/p75 binding mainly correlating
with active chromatin markers and RNA polymerase II binding and not restricted to
STRE [24]. LEDGF/p75 was reported to bind VEGF-c promoter in H1299 cells (in ChIP
assays) [25] and upregulate its activity, similar to transactivation of the Hsp27 promoter.
VEGF-c promoter activation was not affected when one STRE site on the promoter was
mutated, but decreased when both STRE sites were mutated. This agrees with our data
that LEDGF/p75 binding to promoter sites may not strictly depend on one HSE or STRE
region, but may depend on interaction with other regions and factors (Chapter Two).
The role of LEDGF/p75 in tethering proteins to chromatin was reported to
resemble a dynamic scan-and-lock mechanism [26]. Non-specific chromatin
scanning/hopping is a common phenomenon of transcription factors. This likely
facilitates targeting of LEDGF binding proteins to random active transcription regions.
Probable existence of low-concentration higher-affinity chromatin-bound states were also
observed, which might result from association with stress-responsive genes promoters, or
from association downstream of transcription start sites of active transcription units [24].
A recent report shows that LEDGF/p75 guides its binding partners to active
transcription sites through recognition of negative supercoils generated around it [27].
This chromatin binding is facilitated by the novel supercoiled DNA-recognition domain
(SRD), designating a new role for the N-terminal CR2 region (res 200-336). LEDGF/p75
charged regions CR1 and CR2 were previously suggested to be involved in electrostatic
interaction with DNA and chromatin [28]. Expression of LEDGF/p75 fused to E. coli
Dam methylase in HeLa cells showed a typical distribution pattern in the nucleus,
overlapping mostly with condensed chromatin regions associated with low transcriptional
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level [24]. However, determination of DNA sites bound by the protein, as mapped in the
ENCODE region by the DamID technique, revealed that its most frequent sites are
transcription units of active genes [24]. The LEDGF/p75-bound chromatin islands also
correlated well with the HIV-1 integration sites. Likewise, MeCP2 has been recently
reported to associate with active promoter sites [29]. It is possible that only a small
fraction of LEDGF is targeted to transcription active chromatin sites and the protein’s
ability to recognize superhelical structure would be a driving force for chromatin
targeting.
In our studies, we showed for the first time the binding of MeCP2 to Hsp27pr
region (Chapter Two) upstream of HSE and STRE sites. Yasui et al. reported that the
majority of MeCP2 binding sites are intergenic or intronic, outside of transcription units
and CpG islands, [30]. MeCP2 was recently reported to bind DNA regardless of
methylation status and does not function primarily in silencing methylated promoters
[30], but also activates transcription through association with other proteins such as
CREB1 [29]. In addition, DNA binding of MeCP2 is enhanced by hydration near a run of
four or more A/T [31]. Even though MeCP2 binding sites have also been shown to be
distant from genes, commonly over 10kb away; our data shows binding of LEDGF and
MeCP2 on the promoter of Hsp27 in close proximity, within 1kb. In order to resolve this,
we examined Hsp27pr region and identified potential MeCP2 binding sites (Appendix I).
In agreement with our data, sequences containing four or more A/T correlated with
MeCP2 location as seen via ChIP assay. We cannot exclude the possibility that transient
interactions might not be captured using formaldehyde crosslinking in ChIP assays, and
only stable MeCP2-DNA interactions are visualized [32].
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Possible Mode of Interactions between LEDGF and MeCP2
Given that LEDGF binds MeCP2 on its N-terminal region, as opposed to Cterminal binding of HIV-IN and menin/MLL complex, its role here might differ from its
typical cargo-chromatin tethering function. LEDGF/p75 may bind chromatin through
interaction with MeCP2, which preferentially recognize hydrated AT runs [31].
Alternatively, as LEDGF/p75 was observed to facilitate HIV integration in AT rich
regions [33], both proteins might compete for DNA binding at AT rich regions and
regulate each other’s function. It is also possible that LEDGF/p75 binding to chromatin
blocks activation site of MeCP2 and disrupts its association with transcription coactivators, consequently repressing transcription (Fig 19).
Alternatively, the many response element binding sites on Hsp27pr suggest the
participation of multiple co-factors in transcription regulation. This interaction could vary
according to promoter context, explaining the different consequences of LEDGF-MeCP2
interaction on the three promoters we examined [34]. For example, SOX proteins form
stable transcription factor complexes with a variety of co-regulators to activate or repress
gene transcription [35]. They could possibly simultaneously recruit more than one
transcription factor to regulate gene expression from a single promoter or enhancer [36].
Similar to our observations with U2OS and PC3, transcription regulation of SOX proteins
are also cell-type dependent [35]. Moreover, dynamic pattern of tissue-specific gene
expression coupled with partner protein availability and selectivity, are mechanisms that
underlie specific changes in gene expression associated with cell death decisions [37].
Selective DNA binding of promoters activated by sox proteins and their co-factors is
enhancer context-dependent.
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Figure 19. Proposed model of Hsp27 promoter transactivation. We propose that
LEDGF/p75-MeCP2-mediated transactivation of Hsp27pr is dependent on intracellular
protein levels and cellular context. In the presence of LEDGF/p75, MeCP2 is prevented
from interacting with co-activators required for transactivation of Hsp27pr. In the
absence of LEDGF, MeCP2 binds to co-activators such as menin and up-regulates
Hsp27pr activity. Binding of p52 to MeCP2 seems to repress Hsp27pr activation,
possibly due to interaction with a different set of proteins that potentially induces
apoptosis.
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Another example is Cyclic AMP-dependent transcription factor 3 (ATF3), whose
role in transcriptional regulation is decided by the presence or absence of other
ATF/CREB family members [38]. ATF3 is also involved in oncogenesis by increasing
proliferation in DU145 PCa cells [39] and promoting motility and invasiveness of PC3
metastatic derivative MM cells [40]. Conversely, its overexpression results in increased
apoptosis of PC3 cells [41]. Furthermore, the transactivation properties of LEDGF/p75
may depend on its ability to form homodimers or heterodimers with other transcription
co-factors, similar to its interaction with tetramers of HIV IN [42]. LEDGF/p52 , which
antagonizes LEDGF/p75 and has pro-apoptotic functions [43] may compete with
LEDGF/p75 in binding to MeCP2 and Hsp27pr. Following this assumption, the Cterminal domain lacking p52 may not confer survival because of its inability to interact
with survival proteins. We cannot exclude the possibility that these proteins might bind to
each other and stress promoter regions only during stress conditions.

Role of the PWWP Domain in Chromatin and Protein Binding
The PWWP domain is a member of the Tudor “Royal Family” implicated in
chromatin remodeling during DNA repair, replication, transcription and recombination
[44]. This domain is highly conserved in proteins with diverse functions, including the
hepatoma-derived growth factor (HDGF) family, DNA repair and methylation proteins,
transcription factors, and chromatin-associated proteins. DNA methyltransferase proteins
(Dnmt) associates with chromatin via PWWP domains to establish genomic DNA
methylation patterns during development [45]. The Nuclear magnetic resonance (NMR)
solution structure of the PWWP domain of HDGF family shows a five-stranded
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antiparallel β-barrel with a solvent-exposed hydrophobic cavity suggested to bind
chromatin. This chromatin binding property is supported by its electrostatic charge
distribution, which surrounds the binding cavity [46]. Recently, the PWWP domain has
been shown to be crucial for locking LEDGF/p75 and its binding protein on chromatin
[26]. On the other hand, the β-sheets of the bHLH-PAS family (Per-Arnt/AhR-Sim basic
helix-loop-helix), which has a structure similar to that of the PWWP domain, have been
implicated in inter- or intra-protein interactions [47]. In HDGF protein, nuclear
localization signals downstream of its PWWP domain were required for its stimulation of
DNA replication [48, 49]. HDGF was also showed to repress SMYD1 (SET and MYND
domain containing 1) gene expression through its binding to C-terminal binding protein
[50]. Likewise, the similar structure of LEDGF PWWP suggests its involvement in
chromatin and protein binding.

PWWP Domain Represses Transcription
As mentioned before, caspase-mediated cleavage of proteins convert them into
functionally inactive fragments or fragments exhibiting dominant-interfering functions
that amplify the cell death process [51]. Cleavage may impair post translational
modifications necessary for transcriptional activity. For example, caspases-mediated
cleavage of NF-κB p65 (RelA) subunit produces a dominant-negative fragment that is
capable of binding DNA but has no transactivating potential [52]. The cleavage of Nterminal region of LEDGF/p75 resulted in substantial up-regulation of Hsp27pr (Chapter
Three); however, the cleavage of both N- and C-terminal of LEDGF/p75 appears to result
in a fragment with reduced transactivation function. This suggests that cleavage of
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LEDGF/p75 at residue 30 abolished the repressive function of N-terminal region. At the
same time, this suggests that the C-terminal region is implicated in transactivation
function. This concurs with previous report, which suggests that N-terminal domain (res
5-62) exhibits auto-transcriptional repression activity and is involved in stabilizing the
LEDGF-DNA binding complex [23].
The PWWP domain has been shown to be involved in recognition of methylated
histones as in the case of Pdp1 (Schizosaccharomyces pombe protein PWWP domain
protein 1), human BRPF1 (bromo and plant homeodomain finger-containing protein 1)
and murine Dnmt3a DNA methyltransferase [53-55]. This suggests PWWP domain
targets either transcriptionally active (H3K36me3) or inactive (H4K20me) signatures,
probably depending on the structural difference among each protein. It is unknown
whether the PWWP domain recognizes methylated histones or other unknown
modifications enriched in heterochromatic regions. Other chromatin factors such as
MeCP2 might be needed for its chromatin interaction.

Post-translational Modifications and Transcriptional Regulation
Both LEDGF/p75 and MeCP2 are predicted to migrate around 60 kDa. However,
immunoblots show LEDGF/p75 migrating around 75 kDa, correlating with migration of
ectopic expression of Flag-tagged MeCP2. Since both proteins are relatively unstructured
[1, 56] , this suggests the involvement of post-translational modifications. MeCP2 has
been associated with binding methylated CpG islands, and represses transcription through
interaction with histone modifying enzymes such as histone deacetylases (HDACs) and
its co-repressor mSin3A, or through chromatin condensation [57]. However, the role of
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LEDGF in methylation remains unknown. Phosphorylation of MeCP2 was suggested to
regulate its intracellular localization during neuronal cell differentiation, and play a
crucial role in its transcription function [58, 59]. This suggest that phosphorylation of
MeCP2 and LEDGF/p75 could potentially modify their transcription of Hsp27. Predicted
post-translational modification sites of LEDGF/p75 were analyzed using the Accelrys
Omiga 2.0 program (Appendix II) [1]. However, functional consequences of LEDGF/p75
phosphorylation remain to be determined. Further analysis should include
phosphorylation and its effect on the interaction of these proteins with Hsp27pr.

SUMOylation of LEDGF and MeCP2
Bueno et al. recently reported that mutations impairing SUMOylation (Small
Ubiquitin-like Modifier) of LEDGF/p75 increases its transcriptional activity, but not that
of p52, suggesting that different molecular mechanisms might be used to activate Hsp27
promoter [60]. SUMOylation of HDGF was reported to abolish its binding to chromatin
[61]. SUMOylation of Dnmt3a disrupts its ability to interact with histone deacetylases
(HDAC1/2), but not with another interaction partner, Dnmt3b [62]. We cannot exclude
the possibility that SUMOylation of a different position could either inhibit or promote
protein-protein interactions. In addition, SUMO-1 modification modulating the biological
effects of HDAC1 by potentiating its histone deacetylase activity [63], while
SUMOylation of HDAC4 is needed for its transcription repression and histone
deacetylase activity [64]. Sumoylation of coREST (corepressor of RE1 silencing
transcription factor) contributed to its transcriptional repression [65] and might be
involved in regulating histone methylation [66] and Brain-derived neurotrophic factor
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(BDNF) levels in MeCP2 deficient brain [67]. Further experiments should explore the
transactivation functions of LEDGF/p75 SUMOylated mutants.
Immunoblotting analysis showed SUMOylation of MeCP2 in neurons, which
likely permits its interaction with DNA-methylation-based gene regulators such as Dnmt3
and HDACs [59]. However, the location of this modification and its function was not
identified. We analyzed potential SUMOylation sites of MeCP2 using a SUMO
prediction software, SUMOsp 2.0. Consensus and non-consensus motifs with high
probability of SUMO modification were located at its N and C terminus (Appendix III).
Analysis of MeCP2 SUMOylation could shed light to its transactivation function and its
interaction with LEDGF/p75 and p52.

Other Implications of LEDGF-MeCP2 Interaction
LEDGF and MeCP2 share similarities through their binding to other proteins with
similar functions, suggesting that their interaction in a complex may extend to other
contexts. We will discuss some that are closely linked below.

mRNA Splicing
Besides conferring a survival advantage to tumor cells, it is possible that the
LEDGF-MeCP2 interaction could modulate RNA splicing activity. MeCP2 is involved in
RNA splicing regulation through its association with RNA-binding protein Y boxbinding protein 1 [68]. LEDGF/p52 have been reported to interact with the essential
splicing factor ASF/SF2 to modulate ASF/SF2-mediated pre-mRNA splicing [69]. Both
proteins show localization in the nucleus, exhibiting dense fine speckles pattern, similar
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to co-localization pattern of cellular pre-mRNA splicing factors with the RNA
polymerase II transcription, supporting the close link between transcription and premRNA splicing [70-74].

Regulation of Olfactory Receptors
Studies of nasal epithelium from patients with Rett syndrome show that the
maturation of olfactory receptor neurons is impeded prior to the time of synapse
formation [75]. Likewise, we have observed down-regulation of several olfactory
receptor genes in Affymetrix global microarray analysis using mRNA from cells
transiently depleted of LEDGF/p75 (Basu, unpublished data). Homozygous LEDGF
mutant mice in C57BL/6 background resulted in perinatal lethality [76], most possibly
because of impeded development of olfactory receptor, which resulted in failure to nurse.
These mice also exhibited craniofacial and skeletal abnormalities similar to those seen in
mice with mutated Hoxa genes, suggesting the link between LEDGF and Hox gene. This
was confirmed by the association of LEDGF to Hoxa9 expression through menin/MLL
complex [77], suggesting the existence of a complementing interacting complex
consisting of LEDGF/p75, MeCP2 and menin/MLL complex. It will be of interest to
explore whether this complex functions in the regulation of olfactory receptors, some of
which have been recently implicated in signal transduction in PCa cells [78-80].

Interaction with Menin
LEDGF/p75 was reported to transport Menin/MLL complex to the nucleus and
bind chromatin [77]. To examine if menin exists in a complex with LEDGF and MeCP2,
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we performed pull down assays and showed binding of menin to MeCP2 (Chapter three).
Like LEDGF/p75, menin is also required for HIV-1 Tat transactivation [81] through its
association with the Ski-interacting protein SKIP. MeCP2 has been reported to bind corepressor c-Ski, which is required for its transcriptional repression [82]. It will be
interesting to examine if MeCP2 modulates HIV-1 transactivation. In addition, menin
was shown to bind estrogen receptor, and enhances its activity in breast cancer cells,
subsequently conferring resistance to tamoxifen [83]. It will be of interest to examine the
role of menin in Hsp27pr transactivation and resistance to stress-induced cell death.

Conclusion and Final Perspectives
The studies presented here show that LEDGF binds to MeCP2 through its Nterminal domain. This interaction also resulted in modulation of LEDGF-MeCP2
transactivation function. In U2OS cells, MeCP2 appears to be a more potent activator of
Hsp27pr than LEDGF/p75, which appears to regulate MeCP2-mediated transactivation of
Hsp27pr. On the other hand, preliminary data shows that LEDGF/p75, in conjunction
with MeCP2, activate ERp57pr and IGFBP5pr in PC3 cells. Therefore, the effects of
LEDGF/p75 on MeCP2-mediated transactivation might be dependent on other coactivators and repressors, and varies with different promoters and cell types. Further
studies on the effect of LEDGF/p75 and MeCP2 on their transactivation function are
necessary for a better understanding of their mechanism.
Even though ChIP binding assays shows binding of protein complexes to DNA, it
does not reveal the exact binding location for each protein. LEDGF/p75 might bind
directly onto DNA response elements on Hsp27pr, or it might bind to other proteins
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associated with the DNA. The same can apply to MeCP2. Alternatively, the presence of
LEDGF/p75 or MeCP2 could strengthen the interaction between the transcription factors
and co-factors, allowing or disrupting their association with chromatin restructuring
proteins. Other experiments such as EMSA should be performed to identify direct
binding of these proteins to Hsp27pr. We cannot exclude the possibility that many
transcription co-factors are involved in Hsp27pr activation, and that a specific
combination of factors are required for transcription initiation, depending on cell type or
environmental stressors.
The mechanism by which LEDGF/p75 interacts with MeCP2 to modulate
transactivation requires further investigation. LEDGF/p75 may serve to tether MeCP2 to
the chromatin, as it does with HIV-1 IN and the Menin/MLL complex. Alternatively,
these proteins might compete for DNA binding and regulate each other’s transcription
function. Furthermore, these interactions could have different consequences on different
promoters, cell type and stress stimulators. Since HSF1 upregulates Hsp70 and Hsp27
expression, it is important to identify the interplay between this proteins and the
LEDGF/p75-MeCP2 complex. Future experiments should include examining how
LEDGF/p75 and MeCP2 fit into HSF1-mediated stimulation of Hsp27 and Hsp70 and
their negative feedback control. Requirement of additional factors might be needed to
determine promoter activation or repression. Alternatively, binding of splice variants or
cleaved fragments with antagonistic functions might result in the different outcomes. The
presence of menin in relation to LEDGF/p75-MeCP2 complex and its role in
transactivation function modulation in tumor cells also deserves further investigation.
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Overall, these studies provide us with clues to understanding the interaction of
transcription complexes involving LEDGF/p75 and their influence on the activation of
stress genes that protect cancer cells from stress-induced cell death. It also emphasizes
the complexity of transcription modulation and the need for extensive studies in
developing novel therapeutic strategies aimed at targeting the transcription proteins that
regulate stress survival pathways and chemoresistance in PCa.
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APPENDIX A
POSSIBLE MECP2 BINDING REGIONS ON HSP27 PROMOTER
Modified from Oesterreich, 1996
CAT-Box
cggctcactgcaacctctgccttctgggttcaagcaattctcctgcctcagcctccccagcagctgcg
SP1
aatacaggcgcccgccaccacacccagctaatttttgtatttttagtagagatggggtttcaccatgttg
ERE
ERE
gccaggctggtctcaaactcctgacctctggtgatcctcccacctcggtctcccaaagtgctgggattaca
ggcgtgagccaccacgcccagcccagactgccttatttttgtatttgtatttattcatttacttattttgagacag
ggttttgctctgtagcccaggctgaagtgcagtggtgcaatccagctcaccacagcctctactcaccggg
gttcaaaggatcctcctgcttcagcctctggagtagctggggccacaggcatgcaccaccatgcccagct
aatttttaaatattttttggtagaagtagggtctcactatgttgcccagactggtctcaaactcctagcctcaag
ggacccttctgccttggcctcccaaagtgctgagattacaggcatgagccatgcacccagcccctttttaa
aatttttttgagagacaagactttgatctgttgcctaggctggagtgcagtggtgagatcatagctcactgca
gcctcaactcctgggctcaagcaccagactccttttatcacattctatctcacacgcgtgtggttccaatcct
gcctctgccacttctcagttgtatgccccaacccaacctgtctggctctgtcctccttaacagaaggacggc
cctggccacgggccacagccagcaacgcttaagcaccagggccggcgagtgccctgccgtggcacg
HSE
gctccagcgtcgcgctctcGAATTCATTTGCTTTCCTTAACGAGAGAAGGTTCCAG
SP1/AP2
ATGAGGGCTGAACCCTCTTCGCCCCGCCCACGGCCCCTGAACGCTGGG
STRE
SP1
ERE
TATA
GGAGGAGTGCATGGGGAGGGGCGGCCCTCAAACGGGTCATTGCCATTA
TATA
ATAGAGACCTCAAACACCGCCTGCTAAAAATACCCGACTGGAGGAGCAT
AAAAGCGCAGCCGAGCCCAGCGCCCCGCACTTTTCTGAGCAGACGTCCA
Met
GAGCAGAGTCAGCCAGCATG
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APPENDIX B
PREDICTED POST-TRANSLATIONAL MODIFICATION OF LEDGF/P75

Predicted post-translational modification of LEDGF/p75 using Accelrys Omiga 2.0.
Only phosphorylation, amination, glycosylation, and myristylation sites are shown here.
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APPENDIX C
PREDICTED SUMOYLATION SITE OF MECP2 BY SUMOSP 2.0

NP_001104262.1
MAAAAAAAPSGGGGGGEEERLEEKSEDQDLQGLKDKPLKFKKVKKDKKEEKE
GKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMY
DDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTS
LDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATS
EGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKA
EADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETV
SIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHH
HHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLE
SDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRT
PVTERVS
Position
44
47
48
375
426

PeptideScore
KKVKKDK
KKDKKEE
KDKKEEK
SPPKKEH
SVCKEEK

3.824
3.176
3.456
0.578
2.691

Cutoff Type
2.64
2.64
2.64
0.13
2.64

Ψ: hydrophobic amino acid
K: Lysine
X: any amino acid
E: Glutamic acid

185

TypeII: Non-consensus
TypeII: Non-consensus
TypeII: Non-consensus
TypeI: ψ-K-X-E
TypeII: Non-consensus

